# The Gingiva from the Tissue Surrounding the Bone to the Tissue Regenerating the Bone: A Systematic Review of the Osteogenic Capacity of Gingival Mesenchymal Stem Cells in Preclinical Studies

Authors: Gamilah Al-Qadhi; Iman Aboushady; Niyaz Al-Sharabi
Journal: Stem Cells International
 (2021)

---

## Abstract

The current review aims to systematically assess the osteogenic capacity of gingiva-derived mesenchymal stem cells (GMSCs) in preclinical studies. A comprehensive electronic search of PubMed, Embase, Web of Science, and Scopus databases, as well as a manual search of relevant references, was performed in June 2020 without date or language restrictions. Eligibility criteria were the following: studies that compared mesenchymal stem cells (MSCs) derived from the gingiva with other MSC sources (in vitro or in vivo) or cell-free scaffold (in vivo) and studies that reported at least one of the following outcomes: osteogenic potential and new bone formation for in vitro and in vivo, respectively. Moreover, the assessment of included studies was conducted using appropriate guidelines. From 646 initial retrieved studies, 35 full-text articles were subjected to further screening and 26 studies were selected (20 in vitro studies and 6 in vivo studies). GMSCs showed great proliferation capacity and expressed recognized mesenchymal stem cell markers, particularly CD90. In vitro, MSC sources including GMSCs were capable of undergoing osteogenic differentiation with less ability in GMSCs, while most in vivo studies confirmed the capacity of GMSCs to regenerate bony defects. Concerning the assessment of methodological quality, in vitro studies met the relevant guideline except in five areas: the sample size calculation, randomization, allocation concealment, implementation, and blinding, and in vivo publications had probably low risk of bias in most domains except in three areas: allocation concealment, attrition, and blinding items.


---

## Body

## 1. Introduction

From autogeneic grafts to NanoBone materials, various therapeutic strategies to promote bone regeneration have been established over the past years. Autogeneic, allogeneic, and xenogeneic bone grafts, different forms of natural or synthetic bone graft substitutes, bioactive molecule-augmented bone graft substitutes, cell-based bone graft substitutes, and NanoBone materials have been reported in preclinical and clinical fields [1].However, their implantation in bone regeneration has been associated with different complications. Although autogeneic grafting is considered the gold standard therapy, donor site pain, extrasurgery demand, increased surgical time, and postoperative infection were reported in several studies as drawbacks. Similarly, allogeneic grafting combined with the absence of osteogenic potential, risk of viral contamination, and lack of biological and mechanical properties due to the irradiation process required for antimicrobial purposes was reported. Further, the disadvantages of xenografts were the lack of osteogenic ability and risk of immune rejection [2].In addition to the lack of osteoinductive capability, slow degradation rate, and lack of mechanical properties, high pressure and temperature processing have been demonstrated in the bone graft substitutes, such as calcium salt-derived ceramics [3]. Augmentation of bone graft substitutes with growth factors such as bone morphogenetic protein results in accelerated bone healing [4]. It is clear that when materials are exposed to a biological environment, protein adsorption occurs immediately and subsequently mediates cell adhesion and proliferation processes. In comparison to conventional materials, nanomaterials may promote greater amounts of specific protein adsorption (e.g., albumin, laminin, collagen, fibronectin, and vitronectin). Not only the greater protein interactions but also the biomimetic size, larger surface area, and better mechanical properties make nanostructured material a good option to increase osteoblast functions (adhesion, proliferation, and differentiation) [5, 6]. Yet, the application of dental nanomaterial may induce cellular toxicity and need more investigations [7].Consequently, these limitations have led researchers to improve the existing techniques or to develop new ones. Among the proposed promising strategy for bone regeneration is stem cell-based therapy, significantly mesenchymal stem cells (MSCs). These cells are considered major key players in transitional regenerative medicine [8], mainly due to their differentiation capacity into specific cell types, profuse secretion of soluble growth factors and cytokines, migration and homing potential to the site of injury, immunomodulatory effects on innate and adaptive immune cells, and anti-inflammatory effects [9].Immunomodulatory and anti-inflammatory effects occur through cell-cell interactions or paracrine activities. Interferon-gamma (IFNγ) combined with Tumor Necrosis Factor (TNF) or Interleukin-1 (IL-1) stimulates MSCs to produce chemokine receptor ligands such as CXC-Chemokine Receptor 3 (CXCR3) ligand, which in turn recruit T cells resulting in the suppression of proliferation and activity of T cells in their local environment. Besides, MSCs mediate immunosuppression by secretion of secretome including cytokines, growth factors, anti-inflammatory factors, and exosomes that inhibit the proliferation and function of proinflammatory cells, such as T Helper 1 (TH1) and/or TH17 cells, macrophages, neutrophils, Natural Killer (NK) cells, and B cells, and stimulate anti-inflammatory cells, such as macrophages and regulatory T and B cells. Further, anti-inflammatory cells inhibit the function of proinflammatory cells and subsequently promote tissue healing [10].MSCs can be used alone or in combination with a scaffold or carrier, which act as an extracellular template allowing stem cells to attach, proliferate, migrate, and differentiate into target cells. Various options in scaffold designing have been developed to direct and enhance osteogenic differentiation, for example, architecture modification (pore size, stiffness, and topography) [6], chemical stimulation through altering and adjusting the ratio of Hydroxyapatite (HA) to tricalcium phosphate (TCP) [11], biochemical stimulation by introduction of bioactive factors like dexamethasone or vitamin C [12], bone-specific growth factors [13], or addition of mineral fillers like Dicalcium Phosphate Dihydrate (DCPD) and hydraulic Calcium Silicate (CaSi) into Polylactic Acid (PLA) scaffolds [14]. More recently, a growing interest in 3D bioprinting techniques led to opening a new chapter for the production of the bioactive scaffold in bone regeneration [15].Furthermore, mechanical stimulation can be used to enhance the proliferation and differentiation of MSCs into specific cell types [16]. In particular, the mechanical strain and biological fluid flow are converted into biochemical signals and then integrated into cellular responses through mechanotransduction. In bone tissue, osteocytes act as sensory cells responsible for this mechanotransduction, while osteoblasts and osteoclasts are the effector cells [17].Several studies have been conducted using bone marrow mesenchymal stem cells (BMSCs) as a gold standard option for bone defects [18–20] and other dental MSC sources [21, 22]. Nevertheless, harvesting inadequate numbers of BMSCs, long expansion culture time, pain, and morbidity that may occur following the aspiration and collection processes still represent a major issue [23]. Therefore, alternative sources from other locations with a sufficient number of cells and easy isolation procedures have prospected. MSCs from oral tissues, including the dental pulp of permanent and deciduous teeth, periodontal ligaments, dental follicles, and dental papillae, were highly committed to differentiate into osteoblasts and bone cell precursors [24]. Furthermore, MSCs from diseased oral tissue, such as the human periapical cysts [14], inflamed dental pulp, and gingiva [25], provide a new tool for bone regeneration.One of the attractive dental MSC sources is the gingiva. It is a part of the oral mucosal tissue, which surrounds and supports the teeth and alveolar bone and has essential roles ranging from acting as a mucosal barrier to participating in oral mucosal immunity. The gingiva also represents the biomedical waste that occurs because of common dental procedures such as tooth removal, gum or periodontal surgery, and dental implant surgery [26]. Recently, stem cells isolated from the gingiva captivate many researchers in the regenerative medicine field to investigate their features and ability to regenerate tissue, including bone [27].A novel population of stem cells from gingival tissue called gingiva-derived mesenchymal stem cells (GMSCs) was isolated from humans and successfully verified by many researchers [28, 29]. Certainly, gingivae contain both neural crest-derived MSCs (90%) and mesoderm-derived MSCs (10%) with distinct stem cell properties. From clinical and laboratory aspects, the gingiva is considered an easily accessible convenient source with a less-invasive biopsy-taking technique and it is attainable to isolate sufficient numbers of MSCs from gingival tissue depending on their high proliferation rate [30].In addition to their trilineage differentiation ability, self-renewal, and expression of mesenchymal surface markers, they exhibited immunomodulatory and anti-inflammatory properties that make them an attractive source for regenerative application [28]. These cells met the standard minimal criteria proposed by the International Society for Cellular Therapy [31]. Along with bone regeneration, previous studies have indicated that GMSCs had the capacity to regenerate the nerve [32, 33], muscle [34], tendon [35], skin [36], and cartilage and synovial tissues [37].Equally important, the systematic reviews are ordinary procedures in clinical trials to assess the clinical efficiency of certain interventions while systematic reviews in the preclinical research community are still uncommon and need more attention to improve preclinical studies and in turn determine the first step in translating research from bench to patient [38].Considering the above background, the current study is aimed at systematically reviewing the efficacy of applying GMSCs, as a newly introduced source, in bone regeneration in preclinical studies. This systematic review based on the following PICOS question: problem/population: bone defect in animal models (in vivo) and cell culture models (in vitro); intervention: GMSCs for both in vitro and in vivo; comparator or control: comparator: other sources (in vitro)/comparator or control: other sources and cell-free groups (in vivo); outcome: osteogenic capacity; and study design: preclinical studies. All items of PICOS have been used to formulate the following research question: will gingiva-derived mesenchymal stem cells be considered comparable or alternative to other MSC sources regarding bone regeneration in preclinical studies?


## 2. Materials and Methods

The current systematic review was conducted in accordance with the following guideline: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [39] (see supplementary material I for the PRISMA checklist).


### 2.1. Protocol Registration

The protocol of the current study was registered at the CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies) website at the following link:https://drive.google.com/file/d/1fkC_zkxGueWPyguYHAUH2SPLnJkwI3gK/view.


### 2.2. PICOS Question

The current systematic review was designed to answer the following question: will gingiva-derived mesenchymal stem cells be considered comparable or alternative to other MSC sources regarding bone regeneration in preclinical studies?


### 2.3. Eligibility Criteria

The eligibility criteria were established depending on the PICOS items. Therefore, any study that met the inclusion criteria was added as an eligible potential study. To be included,in vivo studies should consider the bone as a targeting area, and bone defects were induced in animals either by surgery or by disease regardless of species, age, and sex, as well as in vitro culture studies that compared MSCs derived from the gingiva and other MSC sources, in vivo studies that compared MSCs derived from the healthy gingiva and cell-free scaffold or other MSC sources, and studies that reported at least one of the following outcomes: new bone formation (in vivo) and osteogenic potential (in vitro).On the other hand, publications that have the following criteria were excluded: targeted areas other than the bone, including the skin and gingiva, irrelevant intervention such as the inflamed gingiva, epithelial gingival cells or gingival fibroblasts, or induced pluripotent stem cells, as well as studies using derivatives of GMSCs such as Extracellular Vesicles (EVs), secretome, gene modification and cocultured cells, single-arm studies, reviews, opinion, and case studies.


### 2.4. Search Sources and Strategy

The popular electronic databases were systematically searched to identify the potential preclinical papers that assess the efficiency of GMSCs in regenerating the bone defects or osteodifferentiationin vivo and in vitro, respectively. The research was carried out in June 2020 and included the following databases: PubMed/MEDLINE, Embase, Web of Science, and Scopus, as well as a manual search of the reference lists of the relevant studies.Based on “A step-by-step guide to systematically identify all relevant animal studies” [40], the research strategy was designed according to the type of the research engine using the following Search Component (SC) terms (medical subject headings (MeSH) terms, EMTREE, and free keywords) without date and language restrictions: SC1 (problem): (bone defect OR bone degradation OR bone disease OR bone disorder OR bone loss OR bone deformation OR bone destruction OR bone injury OR bone fracture) AND SC2 (intervention): (gingival mesenchymal stem cell OR gingival mesenchymal stem cells OR gingiva derived mesenchymal stem cell OR gingival tissue derived mesenchymal stem cells OR gingiva derived stromal cell OR gingiva derived stromal cells OR multipotent gingival stromal cell OR multipotent gingiva stromal cells OR multipotent gingiva progenitor cells OR gingiva stem cells) AND SC3 (control or compotator): (unloaded scaffold OR cell free scaffold) AND SC4 (outcome): (bone regeneration OR bone repair OR new bone formation OR bone healing OR bone tissue engineering OR bone remodeling OR osteogenesis OR osseointegration OR osteoconduction, osteogenic capacity (capability) OR osteogenic differentiation OR osteogenic potential) AND SC5 (study design): (animal model OR animal models OR experimental animal OR experimental animals OR laboratory animal OR laboratory animals OR in vivo study OR in vivo study OR in vitro study OR in vitro OR in vitro studies OR in vitro technique OR in vitro techniques OR cell culture technique OR cell culture method OR cell culture techniques OR culture technique OR culture techniques OR preclinical study) (see supplementary material II for the detailed search strategy).


### 2.5. Study Selection

All retrieved citations were imported and combined into the Mendeley folder, and the duplicated results were removed. Following that, two independent researchers (Al-Qadhi and Aboushady) did two phases of selection with specific exclusion items per phase. The first phase involved skimming the title and abstract of retrieved articles and then excluded the irrelevant studies, and the second phase involved scanning the full texts and excluded the irrelevant studies.


#### 2.5.1. Exclusion Criteria of Selection Phase I

(i)
Review, case report, and expert opinion(ii)
Irrelevant intervention, outcome, and problem(iii)
Presence of any cofactors(iv)
Single-arm studies


#### 2.5.2. Exclusion Criteria of Selection Phase II

(i)
Review, case report, and expert opinion(ii)
Irrelevant intervention, outcome, and problem(iii)
Presence of any cofactors(iv)
Absence of MSC source comparator(v)
Mixing cells into one culture(vi)
Derivatives of a source of interestIn case of discrepancies, the two reviewers discussed the item and Al-Sharabi made the final decision. The reasons for exclusion were discussed and documented.


### 2.6. Data Extraction and Data Items

Data was collected and extracted using a preformed table designed by the authors. Forin vitro culture studies, the following items were taken into consideration: study ID (author, year of publication), study design characteristics (experimental groups, source of stem cells, type of isolation method, type of culture medium, osteogenic induction period, density of cells/well, and type of scaffold or carrier if present), and outcome measures (proliferation potential, characterization of MSCs, and osteogenic differentiation).Similarly, forin vivo studies, the following items were reported: study ID (author, year of publication), study design characteristics (experimental groups), animal model characteristics (species, gender, age, weight, and total numbers), intervention characteristics (source of stem cells, dose, mode of delivery, type of scaffold or carrier, and fate tracing), defect characteristics (site, size, way of induction, and time between induction and treatment), and outcome measures (characterization of MSCs, observation time points, method of analysis, and new bone formation).


### 2.7. Critical Appraisal of Individual Studies

To date, there is no specific risk-of-bias tool for quality assessment ofin vitro culture experiments; therefore, we used the guidelines for reporting preclinical in vitro culture studies on dental materials based on the modification of the CONSORT checklist [41]. For in vivo studies, the risk of bias in included studies was evaluated using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk-of-bias tool for animal intervention studies based on the Cochrane Collaboration RoB Tool with modification of some points [42]. The Health Assessment Workplace Collaborative (HAWC) online tool was used to manage the research process [43].


### 2.8. Summary Measures

To measure the primary outcome inin vitro culture studies, evidence of the formation of mineralized nodules was confirmed by Alizarin red staining or by the expression of osteogenic markers. Along the same line, outcome measures for in vivo studies were represented by the new bone formation that was assessed at least by histology, histochemistry, radiography, or gene expression of osteogenic markers.


### 2.9. Synthesis of Results

In the current systematic review, both outcome measures were performed in a qualitative description manner. The qualitative data synthesis was implanted because there was a marked variation in the way of presenting data among studies. Although most studies used the same outcome investigation method, some of them did not provide quantitative data; some of them used specific markers that differ from others and so on. Thus, the authors decided to illustrate the results in a qualitative manner rather than through a meta-analysis by trying the best to categorize data in a relevant chart.


## 2.1. Protocol Registration

The protocol of the current study was registered at the CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies) website at the following link:https://drive.google.com/file/d/1fkC_zkxGueWPyguYHAUH2SPLnJkwI3gK/view.


## 2.2. PICOS Question

The current systematic review was designed to answer the following question: will gingiva-derived mesenchymal stem cells be considered comparable or alternative to other MSC sources regarding bone regeneration in preclinical studies?


## 2.3. Eligibility Criteria

The eligibility criteria were established depending on the PICOS items. Therefore, any study that met the inclusion criteria was added as an eligible potential study. To be included,in vivo studies should consider the bone as a targeting area, and bone defects were induced in animals either by surgery or by disease regardless of species, age, and sex, as well as in vitro culture studies that compared MSCs derived from the gingiva and other MSC sources, in vivo studies that compared MSCs derived from the healthy gingiva and cell-free scaffold or other MSC sources, and studies that reported at least one of the following outcomes: new bone formation (in vivo) and osteogenic potential (in vitro).On the other hand, publications that have the following criteria were excluded: targeted areas other than the bone, including the skin and gingiva, irrelevant intervention such as the inflamed gingiva, epithelial gingival cells or gingival fibroblasts, or induced pluripotent stem cells, as well as studies using derivatives of GMSCs such as Extracellular Vesicles (EVs), secretome, gene modification and cocultured cells, single-arm studies, reviews, opinion, and case studies.


## 2.4. Search Sources and Strategy

The popular electronic databases were systematically searched to identify the potential preclinical papers that assess the efficiency of GMSCs in regenerating the bone defects or osteodifferentiationin vivo and in vitro, respectively. The research was carried out in June 2020 and included the following databases: PubMed/MEDLINE, Embase, Web of Science, and Scopus, as well as a manual search of the reference lists of the relevant studies.Based on “A step-by-step guide to systematically identify all relevant animal studies” [40], the research strategy was designed according to the type of the research engine using the following Search Component (SC) terms (medical subject headings (MeSH) terms, EMTREE, and free keywords) without date and language restrictions: SC1 (problem): (bone defect OR bone degradation OR bone disease OR bone disorder OR bone loss OR bone deformation OR bone destruction OR bone injury OR bone fracture) AND SC2 (intervention): (gingival mesenchymal stem cell OR gingival mesenchymal stem cells OR gingiva derived mesenchymal stem cell OR gingival tissue derived mesenchymal stem cells OR gingiva derived stromal cell OR gingiva derived stromal cells OR multipotent gingival stromal cell OR multipotent gingiva stromal cells OR multipotent gingiva progenitor cells OR gingiva stem cells) AND SC3 (control or compotator): (unloaded scaffold OR cell free scaffold) AND SC4 (outcome): (bone regeneration OR bone repair OR new bone formation OR bone healing OR bone tissue engineering OR bone remodeling OR osteogenesis OR osseointegration OR osteoconduction, osteogenic capacity (capability) OR osteogenic differentiation OR osteogenic potential) AND SC5 (study design): (animal model OR animal models OR experimental animal OR experimental animals OR laboratory animal OR laboratory animals OR in vivo study OR in vivo study OR in vitro study OR in vitro OR in vitro studies OR in vitro technique OR in vitro techniques OR cell culture technique OR cell culture method OR cell culture techniques OR culture technique OR culture techniques OR preclinical study) (see supplementary material II for the detailed search strategy).


## 2.5. Study Selection

All retrieved citations were imported and combined into the Mendeley folder, and the duplicated results were removed. Following that, two independent researchers (Al-Qadhi and Aboushady) did two phases of selection with specific exclusion items per phase. The first phase involved skimming the title and abstract of retrieved articles and then excluded the irrelevant studies, and the second phase involved scanning the full texts and excluded the irrelevant studies.


### 2.5.1. Exclusion Criteria of Selection Phase I

(i)
Review, case report, and expert opinion(ii)
Irrelevant intervention, outcome, and problem(iii)
Presence of any cofactors(iv)
Single-arm studies


### 2.5.2. Exclusion Criteria of Selection Phase II

(i)
Review, case report, and expert opinion(ii)
Irrelevant intervention, outcome, and problem(iii)
Presence of any cofactors(iv)
Absence of MSC source comparator(v)
Mixing cells into one culture(vi)
Derivatives of a source of interestIn case of discrepancies, the two reviewers discussed the item and Al-Sharabi made the final decision. The reasons for exclusion were discussed and documented.


## 2.5.1. Exclusion Criteria of Selection Phase I

(i)
Review, case report, and expert opinion(ii)
Irrelevant intervention, outcome, and problem(iii)
Presence of any cofactors(iv)
Single-arm studies


## 2.5.2. Exclusion Criteria of Selection Phase II

(i)
Review, case report, and expert opinion(ii)
Irrelevant intervention, outcome, and problem(iii)
Presence of any cofactors(iv)
Absence of MSC source comparator(v)
Mixing cells into one culture(vi)
Derivatives of a source of interestIn case of discrepancies, the two reviewers discussed the item and Al-Sharabi made the final decision. The reasons for exclusion were discussed and documented.


## 2.6. Data Extraction and Data Items

Data was collected and extracted using a preformed table designed by the authors. Forin vitro culture studies, the following items were taken into consideration: study ID (author, year of publication), study design characteristics (experimental groups, source of stem cells, type of isolation method, type of culture medium, osteogenic induction period, density of cells/well, and type of scaffold or carrier if present), and outcome measures (proliferation potential, characterization of MSCs, and osteogenic differentiation).Similarly, forin vivo studies, the following items were reported: study ID (author, year of publication), study design characteristics (experimental groups), animal model characteristics (species, gender, age, weight, and total numbers), intervention characteristics (source of stem cells, dose, mode of delivery, type of scaffold or carrier, and fate tracing), defect characteristics (site, size, way of induction, and time between induction and treatment), and outcome measures (characterization of MSCs, observation time points, method of analysis, and new bone formation).


## 2.7. Critical Appraisal of Individual Studies

To date, there is no specific risk-of-bias tool for quality assessment ofin vitro culture experiments; therefore, we used the guidelines for reporting preclinical in vitro culture studies on dental materials based on the modification of the CONSORT checklist [41]. For in vivo studies, the risk of bias in included studies was evaluated using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk-of-bias tool for animal intervention studies based on the Cochrane Collaboration RoB Tool with modification of some points [42]. The Health Assessment Workplace Collaborative (HAWC) online tool was used to manage the research process [43].


## 2.8. Summary Measures

To measure the primary outcome inin vitro culture studies, evidence of the formation of mineralized nodules was confirmed by Alizarin red staining or by the expression of osteogenic markers. Along the same line, outcome measures for in vivo studies were represented by the new bone formation that was assessed at least by histology, histochemistry, radiography, or gene expression of osteogenic markers.


## 2.9. Synthesis of Results

In the current systematic review, both outcome measures were performed in a qualitative description manner. The qualitative data synthesis was implanted because there was a marked variation in the way of presenting data among studies. Although most studies used the same outcome investigation method, some of them did not provide quantitative data; some of them used specific markers that differ from others and so on. Thus, the authors decided to illustrate the results in a qualitative manner rather than through a meta-analysis by trying the best to categorize data in a relevant chart.


## 3. Results

### 3.1. Study Selection

The followed search strategy resulted in the identification of a total of 646 possible relevant studies. Particularly, PubMed, Embase, Web of Science, and Scopus database searching provided 638 citations and manual searching identified additional 8 citations. Then, duplicated records were removed, resulting in 419 articles, and were subjected to skimming based on titles and abstracts. During this selection phase, 384 studies were excluded because they did not meet the criteria. Following that, 35 full-text remaining articles were selected for eligibility, and of these, 9 studies were excluded. The reason for exclusion was found in the supplementary material (see supplementary materialIII for the excluded studies with reasons). The previous steps are represented by the PRISMA flowchart (Figure 1).Figure 1
Flow diagram showing the different phases of literature screening for the systematic review process (editable file: PRISMA flow diagram, Liberati et al. 2009).


### 3.2. Characteristics ofIn Vitro Included Studies

#### 3.2.1. Methods

A total of 26 studies were selected for the current systematic review. Of these, 20in vitro were culture studies [44–63] and 6 were in vivo studies [64–69]. All papers were published in the English language, and the date of publication started in 2009. Regarding in vitro culture studies, most papers used humans as a source of MSCs except four studies that used animal sources such as mice [44, 45], pigs [46], and horses [47]. Concerning in vivo studies, all studies used humans as a source of MSCs except one study that used rabbits [48].An enzymatic method of GMSC isolation was used in allin vivo and in vitro culture studies except in 2 in vitro culture studies where the outgrowth isolation method was used [49, 50]. In three in vitro studies, homogenous GMSCs were obtained after the isolation methods by colony-forming units [51] and fluorescence-activated cell sorting (FACS) [49], while a single-cell cloning method was used in only one in vivo study [52]. The osteogenic induction medium was used in all in vitro culture studies with an induction period that ranged from 14 to 28 days. The density of cells ranged from 2×103 to 2×106. Seven studies used scaffolds or carriers, commonly tricalcium phosphate (TCP) [49, 53–55] and alginate [56–58]. Six studies of 20 studies confirmed the culture results by an ectopic bone formation (Table 1).Table 1
Summary of findings forin vitro studies (methodology).
No.Author and year of publicationSource of stem cellsIsolation methodType of cultureExperimental groupsOsteogenic induction period (days)Density of cells/wellScaffold or carrier if presentStem cell-based intervention (source of interest)Stem cell-based intervention (other sources)Control groupIn vitro studies without confirmation of an ectopic bone formation1Abedian et al. (2020) [59]HumanEnzymaticOIMGMSCsPDLSCsUninduced cells1412×103—2Kamel et al. (2019) [64]HumanEnzymaticOIMGMSCsDPSCsUninduced cells212×105—3Sun et al. (2019) [44]MiceEnzymaticOIMGMSCsBMSCsCell-free medium215×104—4Xing et al. (2019) [61]HumanEnzymatic∗OIMGMSCsDPSCsPDLSCs—212×105—5Angelopoulos et al. (2018) [56]HumanOutgrowthOIMGMSCsDPSCsCell-free medium287×105—6Zhang et al. (2018) [57]HumanEnzymaticOIMGMSCsDPSCsPDLSCsDFSCsBMSCsADSCsUCMSCs—282.5×105—7Ghaderi et al. (2018) [53]HumanEnzymaticOIMGMSCsBFPMSCsUninduced cells211×105—8Aboushady et al. (2018) [62]RatsEnzymaticOIMGMSCsBMSCsSSMSCs—142×103—9Ansari et al. (2017) [54]HumanEnzymaticOIMGMSCsBMSCsCell-free scaffold281×106Alginate-GelMA∗ hydrogel10Kaibuchi et al. (2017) [46]Mini pigEnzymaticOIMGMSCsBMSCsASCsPSCsPDLSCs—211×103—11Gao et al. (2014) [55]HumanEnzymatic∗∗OIMGMSCsPDLSCsDSCs—212×104—12Gay et al. (2014) [49]HumanEnzymatic∗#OIMGMSCsPDLSCsDPSCsBMSCsUninduced cells285×103—13Yang et al. (2013) [60]HumanEnzymaticOIMGMSCsPDLSCsUninduced cells281×105—14Moshaverinia et al. (2012) [45]HumanEnzymaticOIMGMSCsPDLSCsBMSCsCell-free scaffold281×1063D alginateIn vitro studies confirmed the results by ectopic bone formation15Zorin et al. (2014) [63]HumanEnzymaticOIMGMSCsBMSCs—143×103OCP ceramic granules B-TCP16Moshaverinia et al. (2013) [65]HumanEnzymaticOIMGMSCsPDLSCsBMSCsCell-free scaffold280.5‐1×1063D alginate microbeads17Otabe et al. (2012) [50]HumanEnzymaticOIMGMSCsDPSCs—212.5×105B-TCP18Mensing et al. (2011) [47]HorseEnzymaticOIMGMSCsPDLSCsScMSCsUninduced cells350.2×105—19Fournier et al. (2010) [51]HumanOutgrowth#OIMInduced GMPCGMPC (in vitro)BMSCs (ectopic)Gingival fibroblast (in vitro)Cell-free carrier (ectopic)212×106HA carrier20Tomar et al. (2010) [58]HumanEnzymatic##OIMGMSCsBMSCs (ectopic)Cell-free scaffold (ectopic)21-25 (in vitro)10 (ectopic)2‐5×103 (in vitro)1×106 (ectopic)HA/TCP∗The outgrowth method instead of the digestion method to obtain cells from PDL. ∗∗Isolated cells were further selected via the single-cell cloning method. ∗#Homogenous population of cells was obtained by fluorescence-activated cell sorting after the enzymatic isolation method. #GMSCs were obtained by the outgrowth method followed by colony-forming units. ##GMSCs were obtained by two times the enzymatic method, while BMSCs were obtained by density gradient centrifugation using Ficoll-Hypaque.


#### 3.2.2. Type of Interventions

All studies compared GMSCs with dental or nondental MSC sources. In detail, studies compared GMSCs with periodontal ligament stem cells (PDLSCs) [59]; with dental pulp stem cells (DPSCs) [50, 54, 60]; with BMSCs [44, 49, 53, 55]; with buccal fat pad-derived mesenchymal stem cells (BFPMSCs) [53]; with PDLSCs and BMSCs [56, 57]; with PDLSCs and DPSCs [61]; with PDLSCs and dermal stem cells (DSCs) [55]; with PDLSCs and subcutaneous mesenchymal stem cells (ScMSCs) [47]; with BMSCs and submandibular salivary gland-derived mesenchymal stem cells (SSMSCs) [62]; with PDLSCs, DPSCs, and BMSCs [49]; with PDLSCs, BMSCs, adipose-derived stem cells (ADSCs), and periosteum-derived mesenchymal stem cells (PSCs) [46]; and with PDLSCs, DPSCs, DFSCs, BMSCs, ADSCs, and umbilical cord mesenchymal stem cells (UCMSCs) [57] (Table 2).Table 2
Summary of findings forin vitro studies (identification of MSC results).
No.Author and year of publicationProliferation potentialMorphological appearanceFunctional verification (trilineage differentiation)Phenotypic verification (CD markers)GMSCsOther sourcesGMSCsOther sourcesGMSCsOther sourcesGMSCsOther sources1Abedian et al. (2020) [59]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicOsteogenicAdipogenic✓: CD105, CD90, CD73✖: CD34, CD45✓: CD105, CD90, CD73✖: CD34, CD452Kamel et al. (2019) [64]EffectiveSignificantly higherFibroblast spindle-like cellsFibroblast spindle-like cellsNDND✓: CD105, CD90✖: CD45✓: CD105, CD90✖: CD45∗Data not reported3Sun et al. (2019) [44]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90✖: CD45, CD19✓: CD105, CD90✖: CD45, CD194Xing et al. (2019) [61]Significantly higherEffectiveFibroblast spiral-like cellsFibroblast spiral-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR5Angelopoulos et al. (2018) [56]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicAngiogenicOsteogenicAdipogenicChondrogenicAngiogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD45, CD11b, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD45, CD11b, HLA-DR6Zhang et al. (2018) [57]Comparably effectiveSignificantly higher in 4 dental MSCs and UCMSCs than BMSCs & ADSCsFibroblast-like cellsFibroblast-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR7Ghaderi et al. (2018) [53]NDNDNDNDOsteogenicAdipogenicOsteogenicAdipogenic✓: CD166, CD105, CD90, CD73, CD44✖: CD14, CD34, CD45✓: CD166, CD105, CD90, CD73, CD44✖: CD14, CD34, CD458Aboushady et al. (2018) [62]Moderately effective (less than BMSCs and more than SSMSCs)Significantly higher in BMSCsFibroblast spindle-like cellsFibroblast spindle-like cellsNDNDNDND9Ansari et al. (2017) [54]NDNDNDNDOsteogenicOsteogenic✓: CD146, STRO-1✓: CD146, STRO-110Kaibuchi et al. (2017) [46]Highest proliferationHigher proliferation in BMSCs and PDLSCs followed by PSCs and ADSCsNDNDOsteogenicNO: adipogenicOsteogenicAdipogenic✓: CD29, CD44, CD90✖: CD31✓: CD29, CD44, CD90✖: CD3111Gao et al. (2014) [55]Significantly higher than PDLSCs but lower than DSCsEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicOdontogenic∗OsteogenicAdipogenic✓: CD146, CD105, CD90, CD29, STRO-1✖: CD34, CD45✓: CD146, CD105, CD90, CD29, STRO-1✖: CD34, CD4512Gay et al. (2014) [49]NDNDSpindle-like cellsSpindle-like cells appear in immunoflouresence picturesOsteogenicOsteogenic✓: CD105, CD29, STRO-1, integrin b1, SSEA4, OCT4✓: CD105, CD29, STRO-1, integrin b1, SSEA4, OCT413Yang et al. (2013) [60]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD146, CD105, CD90, CD29, STRO-1✖: CD31, CD34✓: CD146, CD105, CD90, CD29, STRO-1✖: CD31, CD3414Moshaverinia et al. (2012) [45]Significantly higher in comparison to BMSCsSignificantly higher in PDLSCs than BMSCsNDNDOsteogenicAdipogenicOsteogenicAdipogenic✓: CD146✓: CD14615Zorin et al. (2014) [63]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD146, CD105, CD90, CD73✖: CD34, CD45✓: CD146, CD105, CD90, CD73✖: CD34, CD4516Moshaverinia et al. (2013) [65]Significantly higherSignificantly higher (PDLSCs)Effective (BMSCs)NDNDOsteogenicOsteogenic✓: CD146, CD73✖: CD34✓: CD146, CD73✖: CD3417Otabe et al. (2012) [50]EffectiveEffectiveNDNDOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD166, CD146, CD105, CD90, CD44✖: CD34, CD45, CD117✓: CD166, CD146, CD105, CD90, CD44✖: CD34, CD45, CD11718Mensing et al. (2011) [47]EffectiveSignificantly higher in ScMSCs followed by PDLSCsFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90✖: CD31✓: CD105, CD90✖: CD3119Fournier et al. (2010) [51]NS (not specified)NSFibroblast-like cellsFibroblast-like cellsOsteogenicAdipogenicChondrogenicND✓: CD146, CD105, CD90, CD73, CD44, CD29, STRO-1✖: CD34, CD45, CD117, CD200, HLA-DR✓: CD105, CD90, CD73, CD44, CD29✖: CD34, CD45, CD117, CD200, HLA-DR20Tomar et al. (2010) [58]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicND✓: CD105, CD90, CD73, CD44, CD29, HLA-ABC✖: CD14, CD34, CD45, HLA-DR (more stable)✓: CD105, CD90, CD73, CD44, CD29✖: CD14, CD34, CD45, HLA-DR


#### 3.2.3. Identification of Interventions

The proliferation rate of GMSCs was significantly higher in 10 studies compared to other MSC sources [44, 50, 51, 53, 55–57, 59, 62, 63]. However, they were proliferated effectively in the remaining studies. Note that 3 studies did not perform the proliferation assessment [58, 64, 65]. MSCs must be characterized by their morphological appearance and functionally identified by differentiating into adipocytes, chondroblasts, and osteoblasts as well as phenotypically by expressing MSC surface markers CD29, CD73, CD90, and CD105, with lacking expression of CD45, CD34, CD14 or CD11b, CD79 alpha or CD19, and human leukocyte antigen-antigen D-related (HLA-DR) surface molecules [31].Clearly, 10 studies verified GMSCs by using three ways of ISCT identification and approved MSC characteristics [44, 46, 47, 49, 50, 53–55, 62, 63]. It is worth mentioning that some studies implemented three ways of ISCT, but two out of three differentiation assays were applied; for instance, GMSCs differentiated into osteoblasts and adipocytes in the following studies [59, 61, 65] and into osteoblasts but not adipocytes in one study [46]. Besides, some articles utilized one out of three required differentiation analyses and revealed that GMSCs differentiated into osteoblasts only [57, 58, 64]. Two studies did not perform multilineage functional verification [45, 60].Most studies carried out immunophenotype analysis and confirmed that all MSC sources were positively expressed MSC markers with the percentage of >95% and were negative for hematopoietic markers with the percentage of <5%, excluding the two studies that did not provide sufficient CD marker analysis [57, 58], and one study did not establish the analysis [62] (Table 3).Table 3
Summary of findings forin vitro studies (primary outcome: osteogenic potential).
No.Author and year of publicationTissue culture stainingGene expression of osteogenic markersType of stainGMSCsOther sourcesControlGMSCsOther sourcesControlIn vitro studies without confirmation of an ectopic bone formation1Abedian et al. (2020) [59]Alizarin red stainingFormation of mineralized nodulesSimilar formation of mineralized nodulesNoneExpressed:ALP (24.2 fold changes)COL1 (3.57 fold changes)Highly expressed:ALP (42.5 fold changes)COL1 (6.17 fold changes)Lowest2Kamel et al. (2019) [64]Alizarin red stainingFormation of mineralized nodulesStronger formation of mineralized nodulesNoneExpressed:ALPOCNHighly expressed:ALPOCNNone3Sun et al. (2019) [44]Alizarin red stainingStronger formation of mineralized nodulesFormation of mineralized nodulesNoneHighly expressed:ALPRunx2OSXOCN (same)Expressed:ALPRunx2OSX (lowest)OCNNoneALP staining & ALP activityDeeper staining in GMSCs compared with BMSCs/significantly higher activityLess staining/activeNone4Xing et al. (2019) [61]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodules in PDLSCs followed by DPSCs—Expressed:ALP (lowest)Runx2OSX (lowest)OCNCOL1Highly expressed:ALP, OSX (higher in PDL)Runx2OCN, COL1 (higher in DP)—5Angelopoulos et al. (2018) [56]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodulesNone———6Zhang et al. (2018) [57]Alizarin red stainingLeast formation of mineralized nodules in GMSCs and UCMSCsStronger formation of mineralized nodules in BMSCs and ADSCs followed by PDLSCs, DFSCs, and DPSCs—Expressed:ALP (same)COL1 (same)OCN (less)Expressed:ALPCOL1OCN—ALP staining & ALP activityLess staining in GMSCs and UCMSCsDeeper staining in BMSCs, ADSCs, PDLSCs, and DFSCs, followed by DPSCs—7Ghaderi et al. (2018) [53]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodulesNoneVery lowly expressed:BMPCOL1BGLAHighly expressed:BMP (733 fold changes)COL1 (282 fold changes)None8Aboushady et al. (2018) [62]Alizarin red stainingModerate formation of mineralized nodulesStronger formation of mineralized nodules in BMSCs and lower in SSMSCs—Moderately expressed:Runx2MMP-13Highly expressed in BMSCs and lower in SSMSCs:Runx2MMP-13—9Ansari et al. (2017) [54]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodules—Expressed:Runx2OCNExpressed:Runx2OCN—Xylenol orange stainingXO-positive labelingXO-positive labeling—10Kaibuchi et al. (2017) [46]Alizarin red stainingLess formation of mineralized nodulesStrongest formation of mineralized nodules in PDLSCs and PSCs followed by BMSCs and ADSCs—Lowly expressed:COL1A1Moderately expressed:COL3A1Highly expressed in BMSCs and PSCs:COL1A1COL3A1—H&EFail to form cell sheetsBMSCs, ADSCs, and PSCs generate cell sheets, while PDLSCs fail to form cell sheets—11Gao et al. (2014) [55]Alizarin red stainingFormation of mineralized nodulesSimilar formation of mineralized nodules in PDLSCsBoth GMSCs and PDLSCs were higher than DSCs—Moderately expressed:ALPRunx2OCNCOL1Highly expressed for PDLSCs and lower for DSCs:ALPRunx2OCNCOL1—ALP activityModerate activityHigher activity in PDLSCs and lower in DSCs—12Gay et al. (2014) [49]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodulesNoneExpressed:Runx2Highly expressed in PDLSCs and various degrees of expression in other sources:Runx2—13Yang et al. (2013) [60]Alizarin red stainingFormation of mineralized nodulesStronger formation of mineralized nodulesNoneExpressed:Runx2OCNCOL1Highly expressed:Runx2OCNCOL1NoneALP staining & ALP activityActiveHigher activityNone14Moshaverinia et al. (2012) [45]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodules in BMSCs and PDLSCsNoneExpressed:Runx2OCNExpressed:Runx2OCNIn vitro studies confirmed the results by ectopic bone formation15Zorin et al. (2014) [63]H&E stainingExhibited Osteoinductive featuresExhibited Osteoinductive featuresLess new bone formation———Immunohisto chemical stainingIntense reaction for OCN, OPN, ALP, and COL1Intense reaction for OCN, OPN, ALP, and COL1Weak reaction16Moshaverinia et al. (2013) [65]Xylenol orange stainingLess formation of mineralized nodulesStrong formation of mineralized nodules in BMSCs followed by PDLSCsNoneHighly expressed:Runx2Bone sialoproteinOCNHighly expressed:Runx2Bone sialoproteinOCNNoneALP activityLowest activitySignificantly higher activity in BMSCs followed by PDLSCsNoneMicro-CTConsiderable bone volume fractionSignificantly larger bone volume fraction in BMSCs and considerable volume in PDLSCsNoneH&E stainingNew bone formationSignificant new bone formation in BMSCs followed by PDLSCsScaffold remnants & CT17Otabe et al. (2012) [50]Alizarin red stainingStronger formation of mineralized bone nodulesStrong formation of mineralized bone nodulesLessHighly expressed:Runx2OCNHighly expressed:Runx2OCNLowest18Mensing et al. (2011) [47]Von Kossa stainingFormation of mineralized nodulesFormation of mineralized nodulesNoneChondrogenic markers onlyChondrogenic markers only—19Fournier et al. (2010) [51]Alizarin red stainingStrong formation of mineralized nodulesStrong formation of mineralized nodulesNone———H&E stainingFormation of the new bone matrixFormation of the new bone matrixNoneALP stainingPositive reactivityPositive reactivityNone20Tomar et al. (2010) [58]Alizarin red stainingStrong formation of mineralized tissueNDExpressed:ALPCOL1OCNCbfa1OsterixNDH&E stainingNew bone formationNew bone formationNoneVon Kossa stainingHighly mineralized tissueHighly mineralized tissueNoneImmunostainingIntense positive reaction for osteogenic marker OCNIntense positive reaction for osteogenic marker OCNNone


#### 3.2.4. Primary Outcomes

To measure the primary outcome ofin vitro culture studies, osteogenic differentiation was confirmed by the formation of mineralized nodules using a histological staining method, particularly Alizarin red staining, and/or by the expression of osteogenic markers. All in vitro culture studies confirmed that MSC sources including GMSCs were capable of undergoing osteogenic differentiation with different degrees. Obviously, eight articles reported that GMSCs had a lower degree of osteogenic potential than other MSC sources [47, 51, 56, 57, 60, 62, 63, 65].However, similar numbers of articles stated that both GMSCs and other MSC sources formed calcified nodules without determining which one is stronger than the other [46, 49, 50, 53, 55, 58, 59, 64]. Only two studies have approved that GMSCs had a stronger ability to form mineralized nodules [44, 54]. One study reported that GMSCs had a moderate osteogenic capability particularly, lower than BMSCs and higher than SSMSCs [62], and another study showed that GMSCs had a similar osteogenic ability to PDLSCs, higher than DSCs [55].Moreover, the majority of studies conducted additional confirmation methods by using stains such as alkaline phosphatase (ALP), Von Kossa, H&E, and immunochemical stains or by gene expression of osteogenic markers. All articles that used gene expression analysis clarified that MSC sources, including GMSCs, expressed the following markers: ALP, Runt-Related Transcription Factor 2 (Runx2), Osteonectin (OCN), COL1, and Osterix (OSX), and the results were in agreement with staining results (Table3).


### 3.3. Characteristics ofIn Vivo Studies

#### 3.3.1. Methods

Due to limitations in the number of animal studies comparing GMSCs with other sources, the authors decided to include animal studies that compare GMSCs with the control groups as well. In addition to negative controls (scaffolds without stem cells) that were used in allin vivo studies, GMSCs were compared with BMSCs [48] and with PDLSCs and BMSCs [66]. Different animal species were used to create the bony defect, rabbits [48], mice [66–68], dogs [69], and rats [52]. The dose ranged from 1×106 to 4×106. Local application of MSCs was documented in four studies [48, 52, 66, 69], while two studies [67, 68] used a systemic delivery. Green fluorescent protein (GFP) was used as a fate tracer in four studies [52, 67–69], whereas PKH26 was used in one study [48], and no fate tracer was applied in one study [66]. Different locations for surgically created defects, including the tibia, maxilla, mandible, and calvaria with defect sizes that ranged from 0.5 mm to 6.0 mm, were used. Besides, various scaffolds include NanoBone [48], Modified Eagle’s Medium (α-MEM) [67, 68], alginate [66], cell sheet [69], and type 1 collagen (COL1) gel [52]. There was no study that mentioned the time between induction and application of intervention, except one [69] (Table 4).Table 4
Summary of findings forin vivo studies (methodology).
No.Author and year of publicationAnimal modelExperimental groups/numberStem cellsBone defectSpecies/strainSex/age (w)WeightSource of interestGMSCsOther sourcesPositive controlNegative controlSourceIsolation methodDoseDelivery methodScaffold or carrierFate tracingSite & diameter (mm)Induction method1Al-Qadhi et al. (2020) [48]New Zealand rabbitM 242.5-3 kgGMSCs/9BMSCs/9—Cell-free scaffold /9RabbitEnzymatic1×106LocalNanoBonePKH26Tibia/6.0Surgical2Sun et al. (2019) [67]C57BL/6J miceNM 821.08 gGMSCs/18——Cell-free medium/18HumanEnzymatic1×106Systematicα-MEMGFPMaxilla/NMDisease induced by ligation3Xu et al. (2014) [68]C57BL/6J miceM 7NMGMSCs/18——Cell-free medium/18HumanEnzymatic1×106Systematicα-MEMGFPMandible/1.5Surgical4Moshaverinia et al. (2014) [66]Beige nude miceNM 20NMGMSCs/4PDLSCs/4BMSCs/4Cell-free scaffold/4HumanEnzymatic4×106LocalRGD-modified alginate—Calvaria/0.5Surgical5Yu et al. (2012) [69]Beagle dogsM 410-11 kgGMSCs/4——Cell-free scaffold/contralateral sideHumanEnzymatic1×104LocalCell sheetGFPMandible/5.0Surgical6Wang et al. (2011) [52]SD ratsF 6-8160-180 gGMSCs/5——Cell-free matrix/5HumanEnzymatic1‐2×106LocalType 1 collagen gelGFPMandible/1.0SurgicalGMSCs/3Cell-free matrix/contralateral sideCalvaria/5.0


#### 3.3.2. Types of Interventions

All studies compared GMSCs with the cell-free scaffold. From 6 studies, one study compared GMSCs to BMSCs [48], and another study compared between GMSCs, BMSCs, and PDLSCs [66].


#### 3.3.3. Identification of Interventions

Four animal studies verified MSCs using three ways of ISCT characterization items. However, one paper affirmed one of three differentiation lineages [66], and one paper did not establish the multilineage differentiation analysis [48] (Table 5).Table 5
Summary of findings for thein vivo studies (primary outcome result: new bone formation).
No.Author and year of publicationMorphological appearanceFunctional verificationPhenotypic verificationGMSCsLast time point/weeksMethod of analysisGMSCsOther sourcesPositive controlNegative control (without stem cells)Statistical analysis1Al-Qadhi et al. (2020) [48]Fibroblast spindle-like cellsND✓: CD105, CD90, CD73, CD29✖: CD34, CD456H&E stainingNew bone formed at the defect bordersNew bone formed at the defect border and at the center, bridging the defect—Newly formed bone restricted to lateral wallsSignificant difference between each stem cell group and the control while nonsignificant between 2 MSC groupsMT stainingAbundance of red color indicating lamellated boneAbundance of red color indicating lamellated bone—Intermingling areas of woven bone and lamellated boneSignificant between each stem cell group and the control while nonsignificant between 2 MSC groups2Sun et al. (2019) [67]Fibroblast spindle-like cellsOsteogenicAdipogenic✓: CD105, CD90, CD73✖: CD454H&E stainingMore newly formed bone and higher alveolar bone heights——Limited newly formed boneSignificant decrease in alveolar bone loss in the stem cell group compared to the controlMT stainingAbundance of red color indicating more mature bone——Less mature bone3Xu et al. (2014) [68]Fibroblast spindle-like cellsOsteogenicAdipogenicChondrogenic✓: CD105, CD73, CD29, CD44, STRO-1✖: CD144, CD31, HLA-DR, CD34, CD453H&E stainingMT#More newly formed bone than the control groupLimited newly formed boneSignificant difference between the stem cell and control groups4Moshaverinia et al. (2014) [66]Fibroblast-like cellsOsteogenic✓: CD146, CD166✖: CD348H&E stainingLow amount of new boneHigh amount of new boneHigh amount of new boneLess newly formed boneSignificant difference between dental stem cell sources and the controlMT stainingViable mature woven bone formation with a lamellate patternViable mature woven bone formation with a lamellate patternViable mature woven bone formation with a lamellate patternBundles of collagenous fibers and unresorbed scaffoldsImmunohistochemical stainingMild expression of Runx2 and OCNStrong expression of Runx2 and OCNStrong expression of Runx2 and OCNNo expressionMicro-CTLower newly formed bone in comparison to BMSCs & PDLSCs—Largest amount of boneNo bone regenerationSignificant difference between dental stem cell sources and the control5Yu et al. (2012) [69]Fibroblast-like cellsOsteogenicAdipogenic✓: CD105, CD90, CD73, CD44, CD29, STRO-1✖: CD14, CD45, CD144, CD31, HLA-DR8H&E stainingMore newly formed bone——Less newly formed boneSignificant difference between the stem cell and control groupsPicrosirius red stainingNo mineralization but newly formed Sharpey’s fibers——No mineralization but newly formed Sharpey’s fibers—6Wang et al. (2011) [52]Fibroblast-like cellsOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD29, STRO-1✖: CD34, CD458H&E stainingNewly formed bone with the well-mineralized trabecular structure——Abundant connective tissue and very limited newly formed boneNRImmunohistochemical stainingStrong expression of GFP, OPN, and COL1——Weak expression of GFP, OPN, and COL1NR


#### 3.3.4. Results of the Primary Outcome

The area of newly formed bone was detected in animal studies using Hematoxylin and Eosin (H&E) staining and/or Masson Trichrome (MT) or immunohistochemical staining. In terms ofin vivo studies, more newly formed bone areas in GMSC groups were detected by H&E staining [48, 52, 67–69] with the exception of one article indicating that GMSCs had lower new bone formation in comparison to PDLSCs and BMSCs [66]. These results were validated by an abundance of red color indicating mature bone formation [48, 67, 68] and strong expression of GFP, Osteopontin (OPN), and COL1 [52] (Table 5).


### 3.4. Critical Appraisal within Sources of Evidence

Allin vitro culture studies lacked particularly five items: the sample size calculation, sequence regeneration except one study which reported that randomization was done but without giving out how they did it [57], allocation concealment except three studies which implemented random slides for examination [47, 62, 63], implementation, and blinding. Concerning other items, most studies followed guidelines for reporting preclinical in vitro studies (see supplementary material IV for the detailed assessment).There are six domains to illustrate the risk of bias in animal studies. The selection domain results showed that not allin vivo studies performed allocation concealment. However, 4 of 6 studies performed randomization and provided similar baseline characteristics of experimental groups [48, 52, 67, 68]. The confounding domain was not applicable in the current systematic review as we excluded any studies that have confounding factors during the first phase of selection. The finding of the performance domain revealed that all studies showed identical experimental conditions among study groups. In contrast, only one study reported that independent researchers performed outcome analysis and gave details about the conditions of animals after the experiment [48]. Furthermore, all studies have a low risk of bias in detecting, reporting, and using appropriate statistical analysis domains. One paper did not use statistical analysis [52] (Figures 2 and 3).Figure 2
An assessment of the risk of bias among animal studies.Figure 3
A study evaluation bar chart showing the percent of studies with each score, for each metric, in animal studies.


### 3.5. Synthesis of Results

For the proliferation rate, the included studies showed four results: GMSCs had a significantly higher proliferation rate than other MSCs (n=10), GMSCs had an effective proliferation rate somewhat similar to other MSCs (n=7), GMSCs had a lower proliferation rate than other MSCs (n=0), and the proliferation rate was unreported (n=3). Regarding the characterization of interventions, the results of the included studies were identified based on three ways of identifications: morphological, functional, and phenotypical features. Data were presented as follows: definitely sufficient ways used to characterize the intervention (3 out 3) (n=14in vitro and 4 in vivo), probably sufficient ways used to characterize the intervention (2 out 3) (n=3in vitro and 2 in vivo), and insufficient ways used to characterize the intervention (1 out of 3) (n=3in vitro).The primary outcome ofin vitro culture studies was described as follows: GMSCs had stronger osteogenic potential than other MSCs (n=2), GMSCs had similar osteogenic potential to other MSCs (n=8), and GMSCs had less osteogenic potential than other MSCs (n=8). Along the same line, the in vivo outcome was presented as follows: more newly formed bone (n=4), comparable newly formed bone (n=1), and less newly formed bone (n=1) (Figure 4).Figure 4
Schematic diagram represents the main finding of the current review.


## 3.1. Study Selection

The followed search strategy resulted in the identification of a total of 646 possible relevant studies. Particularly, PubMed, Embase, Web of Science, and Scopus database searching provided 638 citations and manual searching identified additional 8 citations. Then, duplicated records were removed, resulting in 419 articles, and were subjected to skimming based on titles and abstracts. During this selection phase, 384 studies were excluded because they did not meet the criteria. Following that, 35 full-text remaining articles were selected for eligibility, and of these, 9 studies were excluded. The reason for exclusion was found in the supplementary material (see supplementary materialIII for the excluded studies with reasons). The previous steps are represented by the PRISMA flowchart (Figure 1).Figure 1
Flow diagram showing the different phases of literature screening for the systematic review process (editable file: PRISMA flow diagram, Liberati et al. 2009).


## 3.2. Characteristics ofIn Vitro Included Studies

### 3.2.1. Methods

A total of 26 studies were selected for the current systematic review. Of these, 20in vitro were culture studies [44–63] and 6 were in vivo studies [64–69]. All papers were published in the English language, and the date of publication started in 2009. Regarding in vitro culture studies, most papers used humans as a source of MSCs except four studies that used animal sources such as mice [44, 45], pigs [46], and horses [47]. Concerning in vivo studies, all studies used humans as a source of MSCs except one study that used rabbits [48].An enzymatic method of GMSC isolation was used in allin vivo and in vitro culture studies except in 2 in vitro culture studies where the outgrowth isolation method was used [49, 50]. In three in vitro studies, homogenous GMSCs were obtained after the isolation methods by colony-forming units [51] and fluorescence-activated cell sorting (FACS) [49], while a single-cell cloning method was used in only one in vivo study [52]. The osteogenic induction medium was used in all in vitro culture studies with an induction period that ranged from 14 to 28 days. The density of cells ranged from 2×103 to 2×106. Seven studies used scaffolds or carriers, commonly tricalcium phosphate (TCP) [49, 53–55] and alginate [56–58]. Six studies of 20 studies confirmed the culture results by an ectopic bone formation (Table 1).Table 1
Summary of findings forin vitro studies (methodology).
No.Author and year of publicationSource of stem cellsIsolation methodType of cultureExperimental groupsOsteogenic induction period (days)Density of cells/wellScaffold or carrier if presentStem cell-based intervention (source of interest)Stem cell-based intervention (other sources)Control groupIn vitro studies without confirmation of an ectopic bone formation1Abedian et al. (2020) [59]HumanEnzymaticOIMGMSCsPDLSCsUninduced cells1412×103—2Kamel et al. (2019) [64]HumanEnzymaticOIMGMSCsDPSCsUninduced cells212×105—3Sun et al. (2019) [44]MiceEnzymaticOIMGMSCsBMSCsCell-free medium215×104—4Xing et al. (2019) [61]HumanEnzymatic∗OIMGMSCsDPSCsPDLSCs—212×105—5Angelopoulos et al. (2018) [56]HumanOutgrowthOIMGMSCsDPSCsCell-free medium287×105—6Zhang et al. (2018) [57]HumanEnzymaticOIMGMSCsDPSCsPDLSCsDFSCsBMSCsADSCsUCMSCs—282.5×105—7Ghaderi et al. (2018) [53]HumanEnzymaticOIMGMSCsBFPMSCsUninduced cells211×105—8Aboushady et al. (2018) [62]RatsEnzymaticOIMGMSCsBMSCsSSMSCs—142×103—9Ansari et al. (2017) [54]HumanEnzymaticOIMGMSCsBMSCsCell-free scaffold281×106Alginate-GelMA∗ hydrogel10Kaibuchi et al. (2017) [46]Mini pigEnzymaticOIMGMSCsBMSCsASCsPSCsPDLSCs—211×103—11Gao et al. (2014) [55]HumanEnzymatic∗∗OIMGMSCsPDLSCsDSCs—212×104—12Gay et al. (2014) [49]HumanEnzymatic∗#OIMGMSCsPDLSCsDPSCsBMSCsUninduced cells285×103—13Yang et al. (2013) [60]HumanEnzymaticOIMGMSCsPDLSCsUninduced cells281×105—14Moshaverinia et al. (2012) [45]HumanEnzymaticOIMGMSCsPDLSCsBMSCsCell-free scaffold281×1063D alginateIn vitro studies confirmed the results by ectopic bone formation15Zorin et al. (2014) [63]HumanEnzymaticOIMGMSCsBMSCs—143×103OCP ceramic granules B-TCP16Moshaverinia et al. (2013) [65]HumanEnzymaticOIMGMSCsPDLSCsBMSCsCell-free scaffold280.5‐1×1063D alginate microbeads17Otabe et al. (2012) [50]HumanEnzymaticOIMGMSCsDPSCs—212.5×105B-TCP18Mensing et al. (2011) [47]HorseEnzymaticOIMGMSCsPDLSCsScMSCsUninduced cells350.2×105—19Fournier et al. (2010) [51]HumanOutgrowth#OIMInduced GMPCGMPC (in vitro)BMSCs (ectopic)Gingival fibroblast (in vitro)Cell-free carrier (ectopic)212×106HA carrier20Tomar et al. (2010) [58]HumanEnzymatic##OIMGMSCsBMSCs (ectopic)Cell-free scaffold (ectopic)21-25 (in vitro)10 (ectopic)2‐5×103 (in vitro)1×106 (ectopic)HA/TCP∗The outgrowth method instead of the digestion method to obtain cells from PDL. ∗∗Isolated cells were further selected via the single-cell cloning method. ∗#Homogenous population of cells was obtained by fluorescence-activated cell sorting after the enzymatic isolation method. #GMSCs were obtained by the outgrowth method followed by colony-forming units. ##GMSCs were obtained by two times the enzymatic method, while BMSCs were obtained by density gradient centrifugation using Ficoll-Hypaque.


### 3.2.2. Type of Interventions

All studies compared GMSCs with dental or nondental MSC sources. In detail, studies compared GMSCs with periodontal ligament stem cells (PDLSCs) [59]; with dental pulp stem cells (DPSCs) [50, 54, 60]; with BMSCs [44, 49, 53, 55]; with buccal fat pad-derived mesenchymal stem cells (BFPMSCs) [53]; with PDLSCs and BMSCs [56, 57]; with PDLSCs and DPSCs [61]; with PDLSCs and dermal stem cells (DSCs) [55]; with PDLSCs and subcutaneous mesenchymal stem cells (ScMSCs) [47]; with BMSCs and submandibular salivary gland-derived mesenchymal stem cells (SSMSCs) [62]; with PDLSCs, DPSCs, and BMSCs [49]; with PDLSCs, BMSCs, adipose-derived stem cells (ADSCs), and periosteum-derived mesenchymal stem cells (PSCs) [46]; and with PDLSCs, DPSCs, DFSCs, BMSCs, ADSCs, and umbilical cord mesenchymal stem cells (UCMSCs) [57] (Table 2).Table 2
Summary of findings forin vitro studies (identification of MSC results).
No.Author and year of publicationProliferation potentialMorphological appearanceFunctional verification (trilineage differentiation)Phenotypic verification (CD markers)GMSCsOther sourcesGMSCsOther sourcesGMSCsOther sourcesGMSCsOther sources1Abedian et al. (2020) [59]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicOsteogenicAdipogenic✓: CD105, CD90, CD73✖: CD34, CD45✓: CD105, CD90, CD73✖: CD34, CD452Kamel et al. (2019) [64]EffectiveSignificantly higherFibroblast spindle-like cellsFibroblast spindle-like cellsNDND✓: CD105, CD90✖: CD45✓: CD105, CD90✖: CD45∗Data not reported3Sun et al. (2019) [44]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90✖: CD45, CD19✓: CD105, CD90✖: CD45, CD194Xing et al. (2019) [61]Significantly higherEffectiveFibroblast spiral-like cellsFibroblast spiral-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR5Angelopoulos et al. (2018) [56]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicAngiogenicOsteogenicAdipogenicChondrogenicAngiogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD45, CD11b, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD45, CD11b, HLA-DR6Zhang et al. (2018) [57]Comparably effectiveSignificantly higher in 4 dental MSCs and UCMSCs than BMSCs & ADSCsFibroblast-like cellsFibroblast-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR7Ghaderi et al. (2018) [53]NDNDNDNDOsteogenicAdipogenicOsteogenicAdipogenic✓: CD166, CD105, CD90, CD73, CD44✖: CD14, CD34, CD45✓: CD166, CD105, CD90, CD73, CD44✖: CD14, CD34, CD458Aboushady et al. (2018) [62]Moderately effective (less than BMSCs and more than SSMSCs)Significantly higher in BMSCsFibroblast spindle-like cellsFibroblast spindle-like cellsNDNDNDND9Ansari et al. (2017) [54]NDNDNDNDOsteogenicOsteogenic✓: CD146, STRO-1✓: CD146, STRO-110Kaibuchi et al. (2017) [46]Highest proliferationHigher proliferation in BMSCs and PDLSCs followed by PSCs and ADSCsNDNDOsteogenicNO: adipogenicOsteogenicAdipogenic✓: CD29, CD44, CD90✖: CD31✓: CD29, CD44, CD90✖: CD3111Gao et al. (2014) [55]Significantly higher than PDLSCs but lower than DSCsEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicOdontogenic∗OsteogenicAdipogenic✓: CD146, CD105, CD90, CD29, STRO-1✖: CD34, CD45✓: CD146, CD105, CD90, CD29, STRO-1✖: CD34, CD4512Gay et al. (2014) [49]NDNDSpindle-like cellsSpindle-like cells appear in immunoflouresence picturesOsteogenicOsteogenic✓: CD105, CD29, STRO-1, integrin b1, SSEA4, OCT4✓: CD105, CD29, STRO-1, integrin b1, SSEA4, OCT413Yang et al. (2013) [60]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD146, CD105, CD90, CD29, STRO-1✖: CD31, CD34✓: CD146, CD105, CD90, CD29, STRO-1✖: CD31, CD3414Moshaverinia et al. (2012) [45]Significantly higher in comparison to BMSCsSignificantly higher in PDLSCs than BMSCsNDNDOsteogenicAdipogenicOsteogenicAdipogenic✓: CD146✓: CD14615Zorin et al. (2014) [63]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD146, CD105, CD90, CD73✖: CD34, CD45✓: CD146, CD105, CD90, CD73✖: CD34, CD4516Moshaverinia et al. (2013) [65]Significantly higherSignificantly higher (PDLSCs)Effective (BMSCs)NDNDOsteogenicOsteogenic✓: CD146, CD73✖: CD34✓: CD146, CD73✖: CD3417Otabe et al. (2012) [50]EffectiveEffectiveNDNDOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD166, CD146, CD105, CD90, CD44✖: CD34, CD45, CD117✓: CD166, CD146, CD105, CD90, CD44✖: CD34, CD45, CD11718Mensing et al. (2011) [47]EffectiveSignificantly higher in ScMSCs followed by PDLSCsFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90✖: CD31✓: CD105, CD90✖: CD3119Fournier et al. (2010) [51]NS (not specified)NSFibroblast-like cellsFibroblast-like cellsOsteogenicAdipogenicChondrogenicND✓: CD146, CD105, CD90, CD73, CD44, CD29, STRO-1✖: CD34, CD45, CD117, CD200, HLA-DR✓: CD105, CD90, CD73, CD44, CD29✖: CD34, CD45, CD117, CD200, HLA-DR20Tomar et al. (2010) [58]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicND✓: CD105, CD90, CD73, CD44, CD29, HLA-ABC✖: CD14, CD34, CD45, HLA-DR (more stable)✓: CD105, CD90, CD73, CD44, CD29✖: CD14, CD34, CD45, HLA-DR


### 3.2.3. Identification of Interventions

The proliferation rate of GMSCs was significantly higher in 10 studies compared to other MSC sources [44, 50, 51, 53, 55–57, 59, 62, 63]. However, they were proliferated effectively in the remaining studies. Note that 3 studies did not perform the proliferation assessment [58, 64, 65]. MSCs must be characterized by their morphological appearance and functionally identified by differentiating into adipocytes, chondroblasts, and osteoblasts as well as phenotypically by expressing MSC surface markers CD29, CD73, CD90, and CD105, with lacking expression of CD45, CD34, CD14 or CD11b, CD79 alpha or CD19, and human leukocyte antigen-antigen D-related (HLA-DR) surface molecules [31].Clearly, 10 studies verified GMSCs by using three ways of ISCT identification and approved MSC characteristics [44, 46, 47, 49, 50, 53–55, 62, 63]. It is worth mentioning that some studies implemented three ways of ISCT, but two out of three differentiation assays were applied; for instance, GMSCs differentiated into osteoblasts and adipocytes in the following studies [59, 61, 65] and into osteoblasts but not adipocytes in one study [46]. Besides, some articles utilized one out of three required differentiation analyses and revealed that GMSCs differentiated into osteoblasts only [57, 58, 64]. Two studies did not perform multilineage functional verification [45, 60].Most studies carried out immunophenotype analysis and confirmed that all MSC sources were positively expressed MSC markers with the percentage of >95% and were negative for hematopoietic markers with the percentage of <5%, excluding the two studies that did not provide sufficient CD marker analysis [57, 58], and one study did not establish the analysis [62] (Table 3).Table 3
Summary of findings forin vitro studies (primary outcome: osteogenic potential).
No.Author and year of publicationTissue culture stainingGene expression of osteogenic markersType of stainGMSCsOther sourcesControlGMSCsOther sourcesControlIn vitro studies without confirmation of an ectopic bone formation1Abedian et al. (2020) [59]Alizarin red stainingFormation of mineralized nodulesSimilar formation of mineralized nodulesNoneExpressed:ALP (24.2 fold changes)COL1 (3.57 fold changes)Highly expressed:ALP (42.5 fold changes)COL1 (6.17 fold changes)Lowest2Kamel et al. (2019) [64]Alizarin red stainingFormation of mineralized nodulesStronger formation of mineralized nodulesNoneExpressed:ALPOCNHighly expressed:ALPOCNNone3Sun et al. (2019) [44]Alizarin red stainingStronger formation of mineralized nodulesFormation of mineralized nodulesNoneHighly expressed:ALPRunx2OSXOCN (same)Expressed:ALPRunx2OSX (lowest)OCNNoneALP staining & ALP activityDeeper staining in GMSCs compared with BMSCs/significantly higher activityLess staining/activeNone4Xing et al. (2019) [61]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodules in PDLSCs followed by DPSCs—Expressed:ALP (lowest)Runx2OSX (lowest)OCNCOL1Highly expressed:ALP, OSX (higher in PDL)Runx2OCN, COL1 (higher in DP)—5Angelopoulos et al. (2018) [56]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodulesNone———6Zhang et al. (2018) [57]Alizarin red stainingLeast formation of mineralized nodules in GMSCs and UCMSCsStronger formation of mineralized nodules in BMSCs and ADSCs followed by PDLSCs, DFSCs, and DPSCs—Expressed:ALP (same)COL1 (same)OCN (less)Expressed:ALPCOL1OCN—ALP staining & ALP activityLess staining in GMSCs and UCMSCsDeeper staining in BMSCs, ADSCs, PDLSCs, and DFSCs, followed by DPSCs—7Ghaderi et al. (2018) [53]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodulesNoneVery lowly expressed:BMPCOL1BGLAHighly expressed:BMP (733 fold changes)COL1 (282 fold changes)None8Aboushady et al. (2018) [62]Alizarin red stainingModerate formation of mineralized nodulesStronger formation of mineralized nodules in BMSCs and lower in SSMSCs—Moderately expressed:Runx2MMP-13Highly expressed in BMSCs and lower in SSMSCs:Runx2MMP-13—9Ansari et al. (2017) [54]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodules—Expressed:Runx2OCNExpressed:Runx2OCN—Xylenol orange stainingXO-positive labelingXO-positive labeling—10Kaibuchi et al. (2017) [46]Alizarin red stainingLess formation of mineralized nodulesStrongest formation of mineralized nodules in PDLSCs and PSCs followed by BMSCs and ADSCs—Lowly expressed:COL1A1Moderately expressed:COL3A1Highly expressed in BMSCs and PSCs:COL1A1COL3A1—H&EFail to form cell sheetsBMSCs, ADSCs, and PSCs generate cell sheets, while PDLSCs fail to form cell sheets—11Gao et al. (2014) [55]Alizarin red stainingFormation of mineralized nodulesSimilar formation of mineralized nodules in PDLSCsBoth GMSCs and PDLSCs were higher than DSCs—Moderately expressed:ALPRunx2OCNCOL1Highly expressed for PDLSCs and lower for DSCs:ALPRunx2OCNCOL1—ALP activityModerate activityHigher activity in PDLSCs and lower in DSCs—12Gay et al. (2014) [49]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodulesNoneExpressed:Runx2Highly expressed in PDLSCs and various degrees of expression in other sources:Runx2—13Yang et al. (2013) [60]Alizarin red stainingFormation of mineralized nodulesStronger formation of mineralized nodulesNoneExpressed:Runx2OCNCOL1Highly expressed:Runx2OCNCOL1NoneALP staining & ALP activityActiveHigher activityNone14Moshaverinia et al. (2012) [45]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodules in BMSCs and PDLSCsNoneExpressed:Runx2OCNExpressed:Runx2OCNIn vitro studies confirmed the results by ectopic bone formation15Zorin et al. (2014) [63]H&E stainingExhibited Osteoinductive featuresExhibited Osteoinductive featuresLess new bone formation———Immunohisto chemical stainingIntense reaction for OCN, OPN, ALP, and COL1Intense reaction for OCN, OPN, ALP, and COL1Weak reaction16Moshaverinia et al. (2013) [65]Xylenol orange stainingLess formation of mineralized nodulesStrong formation of mineralized nodules in BMSCs followed by PDLSCsNoneHighly expressed:Runx2Bone sialoproteinOCNHighly expressed:Runx2Bone sialoproteinOCNNoneALP activityLowest activitySignificantly higher activity in BMSCs followed by PDLSCsNoneMicro-CTConsiderable bone volume fractionSignificantly larger bone volume fraction in BMSCs and considerable volume in PDLSCsNoneH&E stainingNew bone formationSignificant new bone formation in BMSCs followed by PDLSCsScaffold remnants & CT17Otabe et al. (2012) [50]Alizarin red stainingStronger formation of mineralized bone nodulesStrong formation of mineralized bone nodulesLessHighly expressed:Runx2OCNHighly expressed:Runx2OCNLowest18Mensing et al. (2011) [47]Von Kossa stainingFormation of mineralized nodulesFormation of mineralized nodulesNoneChondrogenic markers onlyChondrogenic markers only—19Fournier et al. (2010) [51]Alizarin red stainingStrong formation of mineralized nodulesStrong formation of mineralized nodulesNone———H&E stainingFormation of the new bone matrixFormation of the new bone matrixNoneALP stainingPositive reactivityPositive reactivityNone20Tomar et al. (2010) [58]Alizarin red stainingStrong formation of mineralized tissueNDExpressed:ALPCOL1OCNCbfa1OsterixNDH&E stainingNew bone formationNew bone formationNoneVon Kossa stainingHighly mineralized tissueHighly mineralized tissueNoneImmunostainingIntense positive reaction for osteogenic marker OCNIntense positive reaction for osteogenic marker OCNNone


### 3.2.4. Primary Outcomes

To measure the primary outcome ofin vitro culture studies, osteogenic differentiation was confirmed by the formation of mineralized nodules using a histological staining method, particularly Alizarin red staining, and/or by the expression of osteogenic markers. All in vitro culture studies confirmed that MSC sources including GMSCs were capable of undergoing osteogenic differentiation with different degrees. Obviously, eight articles reported that GMSCs had a lower degree of osteogenic potential than other MSC sources [47, 51, 56, 57, 60, 62, 63, 65].However, similar numbers of articles stated that both GMSCs and other MSC sources formed calcified nodules without determining which one is stronger than the other [46, 49, 50, 53, 55, 58, 59, 64]. Only two studies have approved that GMSCs had a stronger ability to form mineralized nodules [44, 54]. One study reported that GMSCs had a moderate osteogenic capability particularly, lower than BMSCs and higher than SSMSCs [62], and another study showed that GMSCs had a similar osteogenic ability to PDLSCs, higher than DSCs [55].Moreover, the majority of studies conducted additional confirmation methods by using stains such as alkaline phosphatase (ALP), Von Kossa, H&E, and immunochemical stains or by gene expression of osteogenic markers. All articles that used gene expression analysis clarified that MSC sources, including GMSCs, expressed the following markers: ALP, Runt-Related Transcription Factor 2 (Runx2), Osteonectin (OCN), COL1, and Osterix (OSX), and the results were in agreement with staining results (Table3).


## 3.2.1. Methods

A total of 26 studies were selected for the current systematic review. Of these, 20in vitro were culture studies [44–63] and 6 were in vivo studies [64–69]. All papers were published in the English language, and the date of publication started in 2009. Regarding in vitro culture studies, most papers used humans as a source of MSCs except four studies that used animal sources such as mice [44, 45], pigs [46], and horses [47]. Concerning in vivo studies, all studies used humans as a source of MSCs except one study that used rabbits [48].An enzymatic method of GMSC isolation was used in allin vivo and in vitro culture studies except in 2 in vitro culture studies where the outgrowth isolation method was used [49, 50]. In three in vitro studies, homogenous GMSCs were obtained after the isolation methods by colony-forming units [51] and fluorescence-activated cell sorting (FACS) [49], while a single-cell cloning method was used in only one in vivo study [52]. The osteogenic induction medium was used in all in vitro culture studies with an induction period that ranged from 14 to 28 days. The density of cells ranged from 2×103 to 2×106. Seven studies used scaffolds or carriers, commonly tricalcium phosphate (TCP) [49, 53–55] and alginate [56–58]. Six studies of 20 studies confirmed the culture results by an ectopic bone formation (Table 1).Table 1
Summary of findings forin vitro studies (methodology).
No.Author and year of publicationSource of stem cellsIsolation methodType of cultureExperimental groupsOsteogenic induction period (days)Density of cells/wellScaffold or carrier if presentStem cell-based intervention (source of interest)Stem cell-based intervention (other sources)Control groupIn vitro studies without confirmation of an ectopic bone formation1Abedian et al. (2020) [59]HumanEnzymaticOIMGMSCsPDLSCsUninduced cells1412×103—2Kamel et al. (2019) [64]HumanEnzymaticOIMGMSCsDPSCsUninduced cells212×105—3Sun et al. (2019) [44]MiceEnzymaticOIMGMSCsBMSCsCell-free medium215×104—4Xing et al. (2019) [61]HumanEnzymatic∗OIMGMSCsDPSCsPDLSCs—212×105—5Angelopoulos et al. (2018) [56]HumanOutgrowthOIMGMSCsDPSCsCell-free medium287×105—6Zhang et al. (2018) [57]HumanEnzymaticOIMGMSCsDPSCsPDLSCsDFSCsBMSCsADSCsUCMSCs—282.5×105—7Ghaderi et al. (2018) [53]HumanEnzymaticOIMGMSCsBFPMSCsUninduced cells211×105—8Aboushady et al. (2018) [62]RatsEnzymaticOIMGMSCsBMSCsSSMSCs—142×103—9Ansari et al. (2017) [54]HumanEnzymaticOIMGMSCsBMSCsCell-free scaffold281×106Alginate-GelMA∗ hydrogel10Kaibuchi et al. (2017) [46]Mini pigEnzymaticOIMGMSCsBMSCsASCsPSCsPDLSCs—211×103—11Gao et al. (2014) [55]HumanEnzymatic∗∗OIMGMSCsPDLSCsDSCs—212×104—12Gay et al. (2014) [49]HumanEnzymatic∗#OIMGMSCsPDLSCsDPSCsBMSCsUninduced cells285×103—13Yang et al. (2013) [60]HumanEnzymaticOIMGMSCsPDLSCsUninduced cells281×105—14Moshaverinia et al. (2012) [45]HumanEnzymaticOIMGMSCsPDLSCsBMSCsCell-free scaffold281×1063D alginateIn vitro studies confirmed the results by ectopic bone formation15Zorin et al. (2014) [63]HumanEnzymaticOIMGMSCsBMSCs—143×103OCP ceramic granules B-TCP16Moshaverinia et al. (2013) [65]HumanEnzymaticOIMGMSCsPDLSCsBMSCsCell-free scaffold280.5‐1×1063D alginate microbeads17Otabe et al. (2012) [50]HumanEnzymaticOIMGMSCsDPSCs—212.5×105B-TCP18Mensing et al. (2011) [47]HorseEnzymaticOIMGMSCsPDLSCsScMSCsUninduced cells350.2×105—19Fournier et al. (2010) [51]HumanOutgrowth#OIMInduced GMPCGMPC (in vitro)BMSCs (ectopic)Gingival fibroblast (in vitro)Cell-free carrier (ectopic)212×106HA carrier20Tomar et al. (2010) [58]HumanEnzymatic##OIMGMSCsBMSCs (ectopic)Cell-free scaffold (ectopic)21-25 (in vitro)10 (ectopic)2‐5×103 (in vitro)1×106 (ectopic)HA/TCP∗The outgrowth method instead of the digestion method to obtain cells from PDL. ∗∗Isolated cells were further selected via the single-cell cloning method. ∗#Homogenous population of cells was obtained by fluorescence-activated cell sorting after the enzymatic isolation method. #GMSCs were obtained by the outgrowth method followed by colony-forming units. ##GMSCs were obtained by two times the enzymatic method, while BMSCs were obtained by density gradient centrifugation using Ficoll-Hypaque.


## 3.2.2. Type of Interventions

All studies compared GMSCs with dental or nondental MSC sources. In detail, studies compared GMSCs with periodontal ligament stem cells (PDLSCs) [59]; with dental pulp stem cells (DPSCs) [50, 54, 60]; with BMSCs [44, 49, 53, 55]; with buccal fat pad-derived mesenchymal stem cells (BFPMSCs) [53]; with PDLSCs and BMSCs [56, 57]; with PDLSCs and DPSCs [61]; with PDLSCs and dermal stem cells (DSCs) [55]; with PDLSCs and subcutaneous mesenchymal stem cells (ScMSCs) [47]; with BMSCs and submandibular salivary gland-derived mesenchymal stem cells (SSMSCs) [62]; with PDLSCs, DPSCs, and BMSCs [49]; with PDLSCs, BMSCs, adipose-derived stem cells (ADSCs), and periosteum-derived mesenchymal stem cells (PSCs) [46]; and with PDLSCs, DPSCs, DFSCs, BMSCs, ADSCs, and umbilical cord mesenchymal stem cells (UCMSCs) [57] (Table 2).Table 2
Summary of findings forin vitro studies (identification of MSC results).
No.Author and year of publicationProliferation potentialMorphological appearanceFunctional verification (trilineage differentiation)Phenotypic verification (CD markers)GMSCsOther sourcesGMSCsOther sourcesGMSCsOther sourcesGMSCsOther sources1Abedian et al. (2020) [59]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicOsteogenicAdipogenic✓: CD105, CD90, CD73✖: CD34, CD45✓: CD105, CD90, CD73✖: CD34, CD452Kamel et al. (2019) [64]EffectiveSignificantly higherFibroblast spindle-like cellsFibroblast spindle-like cellsNDND✓: CD105, CD90✖: CD45✓: CD105, CD90✖: CD45∗Data not reported3Sun et al. (2019) [44]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90✖: CD45, CD19✓: CD105, CD90✖: CD45, CD194Xing et al. (2019) [61]Significantly higherEffectiveFibroblast spiral-like cellsFibroblast spiral-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR5Angelopoulos et al. (2018) [56]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicAngiogenicOsteogenicAdipogenicChondrogenicAngiogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD45, CD11b, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD45, CD11b, HLA-DR6Zhang et al. (2018) [57]Comparably effectiveSignificantly higher in 4 dental MSCs and UCMSCs than BMSCs & ADSCsFibroblast-like cellsFibroblast-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR✓: CD105, CD90, CD73, CD44✖: CD34, CD11b, CD19, CD45, HLA-DR7Ghaderi et al. (2018) [53]NDNDNDNDOsteogenicAdipogenicOsteogenicAdipogenic✓: CD166, CD105, CD90, CD73, CD44✖: CD14, CD34, CD45✓: CD166, CD105, CD90, CD73, CD44✖: CD14, CD34, CD458Aboushady et al. (2018) [62]Moderately effective (less than BMSCs and more than SSMSCs)Significantly higher in BMSCsFibroblast spindle-like cellsFibroblast spindle-like cellsNDNDNDND9Ansari et al. (2017) [54]NDNDNDNDOsteogenicOsteogenic✓: CD146, STRO-1✓: CD146, STRO-110Kaibuchi et al. (2017) [46]Highest proliferationHigher proliferation in BMSCs and PDLSCs followed by PSCs and ADSCsNDNDOsteogenicNO: adipogenicOsteogenicAdipogenic✓: CD29, CD44, CD90✖: CD31✓: CD29, CD44, CD90✖: CD3111Gao et al. (2014) [55]Significantly higher than PDLSCs but lower than DSCsEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicOdontogenic∗OsteogenicAdipogenic✓: CD146, CD105, CD90, CD29, STRO-1✖: CD34, CD45✓: CD146, CD105, CD90, CD29, STRO-1✖: CD34, CD4512Gay et al. (2014) [49]NDNDSpindle-like cellsSpindle-like cells appear in immunoflouresence picturesOsteogenicOsteogenic✓: CD105, CD29, STRO-1, integrin b1, SSEA4, OCT4✓: CD105, CD29, STRO-1, integrin b1, SSEA4, OCT413Yang et al. (2013) [60]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD146, CD105, CD90, CD29, STRO-1✖: CD31, CD34✓: CD146, CD105, CD90, CD29, STRO-1✖: CD31, CD3414Moshaverinia et al. (2012) [45]Significantly higher in comparison to BMSCsSignificantly higher in PDLSCs than BMSCsNDNDOsteogenicAdipogenicOsteogenicAdipogenic✓: CD146✓: CD14615Zorin et al. (2014) [63]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD146, CD105, CD90, CD73✖: CD34, CD45✓: CD146, CD105, CD90, CD73✖: CD34, CD4516Moshaverinia et al. (2013) [65]Significantly higherSignificantly higher (PDLSCs)Effective (BMSCs)NDNDOsteogenicOsteogenic✓: CD146, CD73✖: CD34✓: CD146, CD73✖: CD3417Otabe et al. (2012) [50]EffectiveEffectiveNDNDOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD166, CD146, CD105, CD90, CD44✖: CD34, CD45, CD117✓: CD166, CD146, CD105, CD90, CD44✖: CD34, CD45, CD11718Mensing et al. (2011) [47]EffectiveSignificantly higher in ScMSCs followed by PDLSCsFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicOsteogenicAdipogenicChondrogenic✓: CD105, CD90✖: CD31✓: CD105, CD90✖: CD3119Fournier et al. (2010) [51]NS (not specified)NSFibroblast-like cellsFibroblast-like cellsOsteogenicAdipogenicChondrogenicND✓: CD146, CD105, CD90, CD73, CD44, CD29, STRO-1✖: CD34, CD45, CD117, CD200, HLA-DR✓: CD105, CD90, CD73, CD44, CD29✖: CD34, CD45, CD117, CD200, HLA-DR20Tomar et al. (2010) [58]Significantly higherEffectiveFibroblast spindle-like cellsFibroblast spindle-like cellsOsteogenicAdipogenicChondrogenicND✓: CD105, CD90, CD73, CD44, CD29, HLA-ABC✖: CD14, CD34, CD45, HLA-DR (more stable)✓: CD105, CD90, CD73, CD44, CD29✖: CD14, CD34, CD45, HLA-DR


## 3.2.3. Identification of Interventions

The proliferation rate of GMSCs was significantly higher in 10 studies compared to other MSC sources [44, 50, 51, 53, 55–57, 59, 62, 63]. However, they were proliferated effectively in the remaining studies. Note that 3 studies did not perform the proliferation assessment [58, 64, 65]. MSCs must be characterized by their morphological appearance and functionally identified by differentiating into adipocytes, chondroblasts, and osteoblasts as well as phenotypically by expressing MSC surface markers CD29, CD73, CD90, and CD105, with lacking expression of CD45, CD34, CD14 or CD11b, CD79 alpha or CD19, and human leukocyte antigen-antigen D-related (HLA-DR) surface molecules [31].Clearly, 10 studies verified GMSCs by using three ways of ISCT identification and approved MSC characteristics [44, 46, 47, 49, 50, 53–55, 62, 63]. It is worth mentioning that some studies implemented three ways of ISCT, but two out of three differentiation assays were applied; for instance, GMSCs differentiated into osteoblasts and adipocytes in the following studies [59, 61, 65] and into osteoblasts but not adipocytes in one study [46]. Besides, some articles utilized one out of three required differentiation analyses and revealed that GMSCs differentiated into osteoblasts only [57, 58, 64]. Two studies did not perform multilineage functional verification [45, 60].Most studies carried out immunophenotype analysis and confirmed that all MSC sources were positively expressed MSC markers with the percentage of >95% and were negative for hematopoietic markers with the percentage of <5%, excluding the two studies that did not provide sufficient CD marker analysis [57, 58], and one study did not establish the analysis [62] (Table 3).Table 3
Summary of findings forin vitro studies (primary outcome: osteogenic potential).
No.Author and year of publicationTissue culture stainingGene expression of osteogenic markersType of stainGMSCsOther sourcesControlGMSCsOther sourcesControlIn vitro studies without confirmation of an ectopic bone formation1Abedian et al. (2020) [59]Alizarin red stainingFormation of mineralized nodulesSimilar formation of mineralized nodulesNoneExpressed:ALP (24.2 fold changes)COL1 (3.57 fold changes)Highly expressed:ALP (42.5 fold changes)COL1 (6.17 fold changes)Lowest2Kamel et al. (2019) [64]Alizarin red stainingFormation of mineralized nodulesStronger formation of mineralized nodulesNoneExpressed:ALPOCNHighly expressed:ALPOCNNone3Sun et al. (2019) [44]Alizarin red stainingStronger formation of mineralized nodulesFormation of mineralized nodulesNoneHighly expressed:ALPRunx2OSXOCN (same)Expressed:ALPRunx2OSX (lowest)OCNNoneALP staining & ALP activityDeeper staining in GMSCs compared with BMSCs/significantly higher activityLess staining/activeNone4Xing et al. (2019) [61]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodules in PDLSCs followed by DPSCs—Expressed:ALP (lowest)Runx2OSX (lowest)OCNCOL1Highly expressed:ALP, OSX (higher in PDL)Runx2OCN, COL1 (higher in DP)—5Angelopoulos et al. (2018) [56]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodulesNone———6Zhang et al. (2018) [57]Alizarin red stainingLeast formation of mineralized nodules in GMSCs and UCMSCsStronger formation of mineralized nodules in BMSCs and ADSCs followed by PDLSCs, DFSCs, and DPSCs—Expressed:ALP (same)COL1 (same)OCN (less)Expressed:ALPCOL1OCN—ALP staining & ALP activityLess staining in GMSCs and UCMSCsDeeper staining in BMSCs, ADSCs, PDLSCs, and DFSCs, followed by DPSCs—7Ghaderi et al. (2018) [53]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodulesNoneVery lowly expressed:BMPCOL1BGLAHighly expressed:BMP (733 fold changes)COL1 (282 fold changes)None8Aboushady et al. (2018) [62]Alizarin red stainingModerate formation of mineralized nodulesStronger formation of mineralized nodules in BMSCs and lower in SSMSCs—Moderately expressed:Runx2MMP-13Highly expressed in BMSCs and lower in SSMSCs:Runx2MMP-13—9Ansari et al. (2017) [54]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodules—Expressed:Runx2OCNExpressed:Runx2OCN—Xylenol orange stainingXO-positive labelingXO-positive labeling—10Kaibuchi et al. (2017) [46]Alizarin red stainingLess formation of mineralized nodulesStrongest formation of mineralized nodules in PDLSCs and PSCs followed by BMSCs and ADSCs—Lowly expressed:COL1A1Moderately expressed:COL3A1Highly expressed in BMSCs and PSCs:COL1A1COL3A1—H&EFail to form cell sheetsBMSCs, ADSCs, and PSCs generate cell sheets, while PDLSCs fail to form cell sheets—11Gao et al. (2014) [55]Alizarin red stainingFormation of mineralized nodulesSimilar formation of mineralized nodules in PDLSCsBoth GMSCs and PDLSCs were higher than DSCs—Moderately expressed:ALPRunx2OCNCOL1Highly expressed for PDLSCs and lower for DSCs:ALPRunx2OCNCOL1—ALP activityModerate activityHigher activity in PDLSCs and lower in DSCs—12Gay et al. (2014) [49]Alizarin red stainingFormation of mineralized nodulesFormation of mineralized nodulesNoneExpressed:Runx2Highly expressed in PDLSCs and various degrees of expression in other sources:Runx2—13Yang et al. (2013) [60]Alizarin red stainingFormation of mineralized nodulesStronger formation of mineralized nodulesNoneExpressed:Runx2OCNCOL1Highly expressed:Runx2OCNCOL1NoneALP staining & ALP activityActiveHigher activityNone14Moshaverinia et al. (2012) [45]Alizarin red stainingLess formation of mineralized nodulesStronger formation of mineralized nodules in BMSCs and PDLSCsNoneExpressed:Runx2OCNExpressed:Runx2OCNIn vitro studies confirmed the results by ectopic bone formation15Zorin et al. (2014) [63]H&E stainingExhibited Osteoinductive featuresExhibited Osteoinductive featuresLess new bone formation———Immunohisto chemical stainingIntense reaction for OCN, OPN, ALP, and COL1Intense reaction for OCN, OPN, ALP, and COL1Weak reaction16Moshaverinia et al. (2013) [65]Xylenol orange stainingLess formation of mineralized nodulesStrong formation of mineralized nodules in BMSCs followed by PDLSCsNoneHighly expressed:Runx2Bone sialoproteinOCNHighly expressed:Runx2Bone sialoproteinOCNNoneALP activityLowest activitySignificantly higher activity in BMSCs followed by PDLSCsNoneMicro-CTConsiderable bone volume fractionSignificantly larger bone volume fraction in BMSCs and considerable volume in PDLSCsNoneH&E stainingNew bone formationSignificant new bone formation in BMSCs followed by PDLSCsScaffold remnants & CT17Otabe et al. (2012) [50]Alizarin red stainingStronger formation of mineralized bone nodulesStrong formation of mineralized bone nodulesLessHighly expressed:Runx2OCNHighly expressed:Runx2OCNLowest18Mensing et al. (2011) [47]Von Kossa stainingFormation of mineralized nodulesFormation of mineralized nodulesNoneChondrogenic markers onlyChondrogenic markers only—19Fournier et al. (2010) [51]Alizarin red stainingStrong formation of mineralized nodulesStrong formation of mineralized nodulesNone———H&E stainingFormation of the new bone matrixFormation of the new bone matrixNoneALP stainingPositive reactivityPositive reactivityNone20Tomar et al. (2010) [58]Alizarin red stainingStrong formation of mineralized tissueNDExpressed:ALPCOL1OCNCbfa1OsterixNDH&E stainingNew bone formationNew bone formationNoneVon Kossa stainingHighly mineralized tissueHighly mineralized tissueNoneImmunostainingIntense positive reaction for osteogenic marker OCNIntense positive reaction for osteogenic marker OCNNone


## 3.2.4. Primary Outcomes

To measure the primary outcome ofin vitro culture studies, osteogenic differentiation was confirmed by the formation of mineralized nodules using a histological staining method, particularly Alizarin red staining, and/or by the expression of osteogenic markers. All in vitro culture studies confirmed that MSC sources including GMSCs were capable of undergoing osteogenic differentiation with different degrees. Obviously, eight articles reported that GMSCs had a lower degree of osteogenic potential than other MSC sources [47, 51, 56, 57, 60, 62, 63, 65].However, similar numbers of articles stated that both GMSCs and other MSC sources formed calcified nodules without determining which one is stronger than the other [46, 49, 50, 53, 55, 58, 59, 64]. Only two studies have approved that GMSCs had a stronger ability to form mineralized nodules [44, 54]. One study reported that GMSCs had a moderate osteogenic capability particularly, lower than BMSCs and higher than SSMSCs [62], and another study showed that GMSCs had a similar osteogenic ability to PDLSCs, higher than DSCs [55].Moreover, the majority of studies conducted additional confirmation methods by using stains such as alkaline phosphatase (ALP), Von Kossa, H&E, and immunochemical stains or by gene expression of osteogenic markers. All articles that used gene expression analysis clarified that MSC sources, including GMSCs, expressed the following markers: ALP, Runt-Related Transcription Factor 2 (Runx2), Osteonectin (OCN), COL1, and Osterix (OSX), and the results were in agreement with staining results (Table3).


## 3.3. Characteristics ofIn Vivo Studies

### 3.3.1. Methods

Due to limitations in the number of animal studies comparing GMSCs with other sources, the authors decided to include animal studies that compare GMSCs with the control groups as well. In addition to negative controls (scaffolds without stem cells) that were used in allin vivo studies, GMSCs were compared with BMSCs [48] and with PDLSCs and BMSCs [66]. Different animal species were used to create the bony defect, rabbits [48], mice [66–68], dogs [69], and rats [52]. The dose ranged from 1×106 to 4×106. Local application of MSCs was documented in four studies [48, 52, 66, 69], while two studies [67, 68] used a systemic delivery. Green fluorescent protein (GFP) was used as a fate tracer in four studies [52, 67–69], whereas PKH26 was used in one study [48], and no fate tracer was applied in one study [66]. Different locations for surgically created defects, including the tibia, maxilla, mandible, and calvaria with defect sizes that ranged from 0.5 mm to 6.0 mm, were used. Besides, various scaffolds include NanoBone [48], Modified Eagle’s Medium (α-MEM) [67, 68], alginate [66], cell sheet [69], and type 1 collagen (COL1) gel [52]. There was no study that mentioned the time between induction and application of intervention, except one [69] (Table 4).Table 4
Summary of findings forin vivo studies (methodology).
No.Author and year of publicationAnimal modelExperimental groups/numberStem cellsBone defectSpecies/strainSex/age (w)WeightSource of interestGMSCsOther sourcesPositive controlNegative controlSourceIsolation methodDoseDelivery methodScaffold or carrierFate tracingSite & diameter (mm)Induction method1Al-Qadhi et al. (2020) [48]New Zealand rabbitM 242.5-3 kgGMSCs/9BMSCs/9—Cell-free scaffold /9RabbitEnzymatic1×106LocalNanoBonePKH26Tibia/6.0Surgical2Sun et al. (2019) [67]C57BL/6J miceNM 821.08 gGMSCs/18——Cell-free medium/18HumanEnzymatic1×106Systematicα-MEMGFPMaxilla/NMDisease induced by ligation3Xu et al. (2014) [68]C57BL/6J miceM 7NMGMSCs/18——Cell-free medium/18HumanEnzymatic1×106Systematicα-MEMGFPMandible/1.5Surgical4Moshaverinia et al. (2014) [66]Beige nude miceNM 20NMGMSCs/4PDLSCs/4BMSCs/4Cell-free scaffold/4HumanEnzymatic4×106LocalRGD-modified alginate—Calvaria/0.5Surgical5Yu et al. (2012) [69]Beagle dogsM 410-11 kgGMSCs/4——Cell-free scaffold/contralateral sideHumanEnzymatic1×104LocalCell sheetGFPMandible/5.0Surgical6Wang et al. (2011) [52]SD ratsF 6-8160-180 gGMSCs/5——Cell-free matrix/5HumanEnzymatic1‐2×106LocalType 1 collagen gelGFPMandible/1.0SurgicalGMSCs/3Cell-free matrix/contralateral sideCalvaria/5.0


### 3.3.2. Types of Interventions

All studies compared GMSCs with the cell-free scaffold. From 6 studies, one study compared GMSCs to BMSCs [48], and another study compared between GMSCs, BMSCs, and PDLSCs [66].


### 3.3.3. Identification of Interventions

Four animal studies verified MSCs using three ways of ISCT characterization items. However, one paper affirmed one of three differentiation lineages [66], and one paper did not establish the multilineage differentiation analysis [48] (Table 5).Table 5
Summary of findings for thein vivo studies (primary outcome result: new bone formation).
No.Author and year of publicationMorphological appearanceFunctional verificationPhenotypic verificationGMSCsLast time point/weeksMethod of analysisGMSCsOther sourcesPositive controlNegative control (without stem cells)Statistical analysis1Al-Qadhi et al. (2020) [48]Fibroblast spindle-like cellsND✓: CD105, CD90, CD73, CD29✖: CD34, CD456H&E stainingNew bone formed at the defect bordersNew bone formed at the defect border and at the center, bridging the defect—Newly formed bone restricted to lateral wallsSignificant difference between each stem cell group and the control while nonsignificant between 2 MSC groupsMT stainingAbundance of red color indicating lamellated boneAbundance of red color indicating lamellated bone—Intermingling areas of woven bone and lamellated boneSignificant between each stem cell group and the control while nonsignificant between 2 MSC groups2Sun et al. (2019) [67]Fibroblast spindle-like cellsOsteogenicAdipogenic✓: CD105, CD90, CD73✖: CD454H&E stainingMore newly formed bone and higher alveolar bone heights——Limited newly formed boneSignificant decrease in alveolar bone loss in the stem cell group compared to the controlMT stainingAbundance of red color indicating more mature bone——Less mature bone3Xu et al. (2014) [68]Fibroblast spindle-like cellsOsteogenicAdipogenicChondrogenic✓: CD105, CD73, CD29, CD44, STRO-1✖: CD144, CD31, HLA-DR, CD34, CD453H&E stainingMT#More newly formed bone than the control groupLimited newly formed boneSignificant difference between the stem cell and control groups4Moshaverinia et al. (2014) [66]Fibroblast-like cellsOsteogenic✓: CD146, CD166✖: CD348H&E stainingLow amount of new boneHigh amount of new boneHigh amount of new boneLess newly formed boneSignificant difference between dental stem cell sources and the controlMT stainingViable mature woven bone formation with a lamellate patternViable mature woven bone formation with a lamellate patternViable mature woven bone formation with a lamellate patternBundles of collagenous fibers and unresorbed scaffoldsImmunohistochemical stainingMild expression of Runx2 and OCNStrong expression of Runx2 and OCNStrong expression of Runx2 and OCNNo expressionMicro-CTLower newly formed bone in comparison to BMSCs & PDLSCs—Largest amount of boneNo bone regenerationSignificant difference between dental stem cell sources and the control5Yu et al. (2012) [69]Fibroblast-like cellsOsteogenicAdipogenic✓: CD105, CD90, CD73, CD44, CD29, STRO-1✖: CD14, CD45, CD144, CD31, HLA-DR8H&E stainingMore newly formed bone——Less newly formed boneSignificant difference between the stem cell and control groupsPicrosirius red stainingNo mineralization but newly formed Sharpey’s fibers——No mineralization but newly formed Sharpey’s fibers—6Wang et al. (2011) [52]Fibroblast-like cellsOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD29, STRO-1✖: CD34, CD458H&E stainingNewly formed bone with the well-mineralized trabecular structure——Abundant connective tissue and very limited newly formed boneNRImmunohistochemical stainingStrong expression of GFP, OPN, and COL1——Weak expression of GFP, OPN, and COL1NR


### 3.3.4. Results of the Primary Outcome

The area of newly formed bone was detected in animal studies using Hematoxylin and Eosin (H&E) staining and/or Masson Trichrome (MT) or immunohistochemical staining. In terms ofin vivo studies, more newly formed bone areas in GMSC groups were detected by H&E staining [48, 52, 67–69] with the exception of one article indicating that GMSCs had lower new bone formation in comparison to PDLSCs and BMSCs [66]. These results were validated by an abundance of red color indicating mature bone formation [48, 67, 68] and strong expression of GFP, Osteopontin (OPN), and COL1 [52] (Table 5).


## 3.3.1. Methods

Due to limitations in the number of animal studies comparing GMSCs with other sources, the authors decided to include animal studies that compare GMSCs with the control groups as well. In addition to negative controls (scaffolds without stem cells) that were used in allin vivo studies, GMSCs were compared with BMSCs [48] and with PDLSCs and BMSCs [66]. Different animal species were used to create the bony defect, rabbits [48], mice [66–68], dogs [69], and rats [52]. The dose ranged from 1×106 to 4×106. Local application of MSCs was documented in four studies [48, 52, 66, 69], while two studies [67, 68] used a systemic delivery. Green fluorescent protein (GFP) was used as a fate tracer in four studies [52, 67–69], whereas PKH26 was used in one study [48], and no fate tracer was applied in one study [66]. Different locations for surgically created defects, including the tibia, maxilla, mandible, and calvaria with defect sizes that ranged from 0.5 mm to 6.0 mm, were used. Besides, various scaffolds include NanoBone [48], Modified Eagle’s Medium (α-MEM) [67, 68], alginate [66], cell sheet [69], and type 1 collagen (COL1) gel [52]. There was no study that mentioned the time between induction and application of intervention, except one [69] (Table 4).Table 4
Summary of findings forin vivo studies (methodology).
No.Author and year of publicationAnimal modelExperimental groups/numberStem cellsBone defectSpecies/strainSex/age (w)WeightSource of interestGMSCsOther sourcesPositive controlNegative controlSourceIsolation methodDoseDelivery methodScaffold or carrierFate tracingSite & diameter (mm)Induction method1Al-Qadhi et al. (2020) [48]New Zealand rabbitM 242.5-3 kgGMSCs/9BMSCs/9—Cell-free scaffold /9RabbitEnzymatic1×106LocalNanoBonePKH26Tibia/6.0Surgical2Sun et al. (2019) [67]C57BL/6J miceNM 821.08 gGMSCs/18——Cell-free medium/18HumanEnzymatic1×106Systematicα-MEMGFPMaxilla/NMDisease induced by ligation3Xu et al. (2014) [68]C57BL/6J miceM 7NMGMSCs/18——Cell-free medium/18HumanEnzymatic1×106Systematicα-MEMGFPMandible/1.5Surgical4Moshaverinia et al. (2014) [66]Beige nude miceNM 20NMGMSCs/4PDLSCs/4BMSCs/4Cell-free scaffold/4HumanEnzymatic4×106LocalRGD-modified alginate—Calvaria/0.5Surgical5Yu et al. (2012) [69]Beagle dogsM 410-11 kgGMSCs/4——Cell-free scaffold/contralateral sideHumanEnzymatic1×104LocalCell sheetGFPMandible/5.0Surgical6Wang et al. (2011) [52]SD ratsF 6-8160-180 gGMSCs/5——Cell-free matrix/5HumanEnzymatic1‐2×106LocalType 1 collagen gelGFPMandible/1.0SurgicalGMSCs/3Cell-free matrix/contralateral sideCalvaria/5.0


## 3.3.2. Types of Interventions

All studies compared GMSCs with the cell-free scaffold. From 6 studies, one study compared GMSCs to BMSCs [48], and another study compared between GMSCs, BMSCs, and PDLSCs [66].


## 3.3.3. Identification of Interventions

Four animal studies verified MSCs using three ways of ISCT characterization items. However, one paper affirmed one of three differentiation lineages [66], and one paper did not establish the multilineage differentiation analysis [48] (Table 5).Table 5
Summary of findings for thein vivo studies (primary outcome result: new bone formation).
No.Author and year of publicationMorphological appearanceFunctional verificationPhenotypic verificationGMSCsLast time point/weeksMethod of analysisGMSCsOther sourcesPositive controlNegative control (without stem cells)Statistical analysis1Al-Qadhi et al. (2020) [48]Fibroblast spindle-like cellsND✓: CD105, CD90, CD73, CD29✖: CD34, CD456H&E stainingNew bone formed at the defect bordersNew bone formed at the defect border and at the center, bridging the defect—Newly formed bone restricted to lateral wallsSignificant difference between each stem cell group and the control while nonsignificant between 2 MSC groupsMT stainingAbundance of red color indicating lamellated boneAbundance of red color indicating lamellated bone—Intermingling areas of woven bone and lamellated boneSignificant between each stem cell group and the control while nonsignificant between 2 MSC groups2Sun et al. (2019) [67]Fibroblast spindle-like cellsOsteogenicAdipogenic✓: CD105, CD90, CD73✖: CD454H&E stainingMore newly formed bone and higher alveolar bone heights——Limited newly formed boneSignificant decrease in alveolar bone loss in the stem cell group compared to the controlMT stainingAbundance of red color indicating more mature bone——Less mature bone3Xu et al. (2014) [68]Fibroblast spindle-like cellsOsteogenicAdipogenicChondrogenic✓: CD105, CD73, CD29, CD44, STRO-1✖: CD144, CD31, HLA-DR, CD34, CD453H&E stainingMT#More newly formed bone than the control groupLimited newly formed boneSignificant difference between the stem cell and control groups4Moshaverinia et al. (2014) [66]Fibroblast-like cellsOsteogenic✓: CD146, CD166✖: CD348H&E stainingLow amount of new boneHigh amount of new boneHigh amount of new boneLess newly formed boneSignificant difference between dental stem cell sources and the controlMT stainingViable mature woven bone formation with a lamellate patternViable mature woven bone formation with a lamellate patternViable mature woven bone formation with a lamellate patternBundles of collagenous fibers and unresorbed scaffoldsImmunohistochemical stainingMild expression of Runx2 and OCNStrong expression of Runx2 and OCNStrong expression of Runx2 and OCNNo expressionMicro-CTLower newly formed bone in comparison to BMSCs & PDLSCs—Largest amount of boneNo bone regenerationSignificant difference between dental stem cell sources and the control5Yu et al. (2012) [69]Fibroblast-like cellsOsteogenicAdipogenic✓: CD105, CD90, CD73, CD44, CD29, STRO-1✖: CD14, CD45, CD144, CD31, HLA-DR8H&E stainingMore newly formed bone——Less newly formed boneSignificant difference between the stem cell and control groupsPicrosirius red stainingNo mineralization but newly formed Sharpey’s fibers——No mineralization but newly formed Sharpey’s fibers—6Wang et al. (2011) [52]Fibroblast-like cellsOsteogenicAdipogenicChondrogenic✓: CD105, CD90, CD29, STRO-1✖: CD34, CD458H&E stainingNewly formed bone with the well-mineralized trabecular structure——Abundant connective tissue and very limited newly formed boneNRImmunohistochemical stainingStrong expression of GFP, OPN, and COL1——Weak expression of GFP, OPN, and COL1NR


## 3.3.4. Results of the Primary Outcome

The area of newly formed bone was detected in animal studies using Hematoxylin and Eosin (H&E) staining and/or Masson Trichrome (MT) or immunohistochemical staining. In terms ofin vivo studies, more newly formed bone areas in GMSC groups were detected by H&E staining [48, 52, 67–69] with the exception of one article indicating that GMSCs had lower new bone formation in comparison to PDLSCs and BMSCs [66]. These results were validated by an abundance of red color indicating mature bone formation [48, 67, 68] and strong expression of GFP, Osteopontin (OPN), and COL1 [52] (Table 5).


## 3.4. Critical Appraisal within Sources of Evidence

Allin vitro culture studies lacked particularly five items: the sample size calculation, sequence regeneration except one study which reported that randomization was done but without giving out how they did it [57], allocation concealment except three studies which implemented random slides for examination [47, 62, 63], implementation, and blinding. Concerning other items, most studies followed guidelines for reporting preclinical in vitro studies (see supplementary material IV for the detailed assessment).There are six domains to illustrate the risk of bias in animal studies. The selection domain results showed that not allin vivo studies performed allocation concealment. However, 4 of 6 studies performed randomization and provided similar baseline characteristics of experimental groups [48, 52, 67, 68]. The confounding domain was not applicable in the current systematic review as we excluded any studies that have confounding factors during the first phase of selection. The finding of the performance domain revealed that all studies showed identical experimental conditions among study groups. In contrast, only one study reported that independent researchers performed outcome analysis and gave details about the conditions of animals after the experiment [48]. Furthermore, all studies have a low risk of bias in detecting, reporting, and using appropriate statistical analysis domains. One paper did not use statistical analysis [52] (Figures 2 and 3).Figure 2
An assessment of the risk of bias among animal studies.Figure 3
A study evaluation bar chart showing the percent of studies with each score, for each metric, in animal studies.


## 3.5. Synthesis of Results

For the proliferation rate, the included studies showed four results: GMSCs had a significantly higher proliferation rate than other MSCs (n=10), GMSCs had an effective proliferation rate somewhat similar to other MSCs (n=7), GMSCs had a lower proliferation rate than other MSCs (n=0), and the proliferation rate was unreported (n=3). Regarding the characterization of interventions, the results of the included studies were identified based on three ways of identifications: morphological, functional, and phenotypical features. Data were presented as follows: definitely sufficient ways used to characterize the intervention (3 out 3) (n=14in vitro and 4 in vivo), probably sufficient ways used to characterize the intervention (2 out 3) (n=3in vitro and 2 in vivo), and insufficient ways used to characterize the intervention (1 out of 3) (n=3in vitro).The primary outcome ofin vitro culture studies was described as follows: GMSCs had stronger osteogenic potential than other MSCs (n=2), GMSCs had similar osteogenic potential to other MSCs (n=8), and GMSCs had less osteogenic potential than other MSCs (n=8). Along the same line, the in vivo outcome was presented as follows: more newly formed bone (n=4), comparable newly formed bone (n=1), and less newly formed bone (n=1) (Figure 4).Figure 4
Schematic diagram represents the main finding of the current review.


## 4. Discussion

The main purpose of this systematic review was to summarize the role of gingiva-derived mesenchymal stem cells (GMSCs) and their effects on osteodifferentiation and bone regeneration bothin vitro and in vivo. Overall, 26 studies were qualitatively reviewed. Twenty in vitro culture studies and six in vivo studies were mainly carried out to evaluate the proliferation and osteodifferentiation potential of GMSCs in comparison to other sources of MSCs or to nontreated GMSCs. The gingiva is recognized as a biological oral barrier against different insults and shows rapid regeneration without scar formation. This ability ascribes to the presence of an abundance of highly proliferative cells. These unique cell populations were firstly identified by Zhang and his colleagues as a cell population with similar stem cell-like properties [28].Currently, these cells are commonly referred to as GMSCs and considered desirable stem cell sources because of their easy accessibility with limited morbidity. The multipotent differentiation capability of GMSCs has also been comparedin vivo and in vitro with other stem cell types such as BMSCs, DPSCs, and PDLSCs. Therefore, the authors of this current review believe that in-depth assessment of the literature on preclinical in vivo and in vitro culture studies of GMSCs in bone tissue engineering and regenerative medicine is of great importance to explore the efficacy of GMSCs as a therapeutic source of MSCs.The use of MSCs in clinical application generally depends on their biological properties including stemness and production of healing secretion factors. MSC is commonly isolated as a plastic-adherent cell population via either the enzymatic digestion method or the nonenzymatic digestion method. Researchers believe that cell isolation and expansion protocols influence stem cell quality, including yield, viability, and differentiation potential. Gingival tissues are commonly obtained after surgical removal of gingival tissue samples and either kept intact to grow out the adherent cells or digested by the use of specific enzymes to obtain single-cell suspensions.Although no study to compare the two common isolation protocols for GMSCs is available to date, the majority of studies in this review display that GMSCs rapidly proliferate after both isolation methods, irrespective of their species. Likewise, in all studies evaluated in the present review, no study attempts to correlate this superior proliferative ability to any specific isolation method. On average, an increased number of cells with highly proliferative properties from the gingiva appeared after the enzymatic method. Among the studies evaluated in this systematic review (only three studies), a homogeneous population of stem cells was further selected using single-cell cloning [52], fluorescence-activated cell sorting [49], and colony-forming units [51].Nevertheless, these data might hinder our precise conclusion of the advantages of isolation and purification methods on GMSC quality. In particular, since MSC quality is influenced by several factors during isolation and expansion producers, we recommend further assessment of GMSC isolation and expansion and establish a standard protocol before translating GMSCs to the clinical application. However, a review article by El-Sayed and Dörfer summarized various protocols of GMSC isolation and expansion and addressed some valuable information to achieve MSCs from gingival tissue [27].To characterize GMSCs and compare their stemness properties to other types of stem cellsin vitro, most of the current reviewed studies met the minimal criteria proposed by the International Society for Cellular Therapy for MSC characterization [31]. Self-renewal ability as a result of either asymmetrical or symmetrical cell division into different cells with distinct properties is considered the first basic cellular characteristic of stem cells. Almost all reviewed studies showed that GMSCs remain in a quiescent state after isolation and then propagate into a spindle-shaped morphology, similar to BMSCs, DPSCs, DPLSCs, ASCs, and others [46].The morphological analysis of GMSCs showed no discernible difference between the reviewed studies as GMSCs displayed a stable phenotype in long-term culture and are nontumorigenic [58]. Likewise, GMSCs demonstrated a high ability for colony formation in two-dimensional (2D) culture and high viability rates in RGD-modified alginate hydrogel microspheres similar to BMSCs [54]. Admittedly, MSCs, as primary cells, show some in vitro proliferation potential and differentiation capability to a certain passage before they undergo considerable cellular alterations and senescence [70, 71]. On the contrary, GMSCs showed some remarkable growth characteristics in comparison to the other stem cell sources. In comparison to BMSCs, Tomar et al. reported that human gingival tissues generated highly proliferative, homogenous fibroblast spindle-like cells with a normal diploid number of chromosomes and normal karyotype even in the late passage [58].Additionally, human GMSCs display highly growth properties than human BMSCs and PDLSCs, while a short doubling time of GMSCs was observed [62, 66]. GMSCs manifested higher proliferative rates than DPSCs at an early passage with more resistance to induced-oxidative stress and aging in long-term culture [61]. These significant properties are attributed to the continuous activation of the telomerase enzyme in GMSCs even in long-term cultures and to the heterogeneity of other types of stem cells [58].On the other hand, GMSCs disclosed some unremarkable proliferative rates in comparison to other sources of stem cells, including human BMSCs [62] and pig BMSCs and PSCs [46]. Moreover, the low colony-forming unit-fibroblast (CFU-F) ability of GMSCs in comparison to human DSCs was reported [55]. The heterogeneity of the data showed in the current review of the literature can be attributed either to the donor- and tissue-dependent variations or to the cell isolation and expansion procedures. Substantial cell-to-cell variation among MSCs within a single population is thought to play a significant role in the experiments and outcomes [72]. Further studies are needed to investigate the effects of different culture conditions and properties of different GMSC subpopulations.Nevertheless, the colony-forming assay with increased cell growth demonstrated that GMSCs exhibit a significantly higher proliferation potential than other stem cell sources. This result may be due to the biological function of the gingiva because it shows some exceptional reparative/regenerative potential after wounding. In terms of easyin vitro isolation with a large scale of cell expansion without significant phenotype and genotype alterations, GMSCs can be used as an attractive alternative source to BMSCs in stem cell research studies. Similar to standard characterizations of MSCs from other tissue sources, almost all the reviewed studies showed that GMSCs uniformly expressed certain stem cell markers, including CD90, CD105, CD146, and CD73 (all above 95%), and did not express hematopoietic stem cell markers CD45 and CD35. Even though the gingiva is densely vascular, these data might confirm the stromal origin of isolated cells without contamination with hematopoietic precursor cells.However, this might not be necessarily correlated with the ability of MSCs to differentiate into other types of cells, including bone-forming cells. The majority of studies in the current review show the ability of GMSCs forin vitro osteodifferentiation under established osteoblast lineage-specific factors with remarkable changes in protein, gene, and miRNA levels. Unremarkable findings respective to GMSC osteodifferentiation potential in comparison to other stem cell types were also shown. GMSCs displayed less osteogenic potential than other MSC sources, while the high expression level of MSC surface markers was reported [47, 51, 56, 57, 62, 63, 65].A study by Gao et al. demonstrated that human GMSCs with higher expression of CD90 in comparison to other stem cells of dental origin, DPSCs and PDLSCs, had a moderate osteogenic potential [55]. Two studies showed that GMSCs had better osteogenic capacity than BMSCs and DPSCs [44, 54]. Successful osteodifferentiation of GMSCs has also been shown in various studies and verified by staining of differentiated cells with Alizarin red or Von Kosssa and/or by expression of bone-related markers including Runx2, ALP, OCN, OPN, OSX, COL1, and COL3 [27]. GMSCs seeded in the 3D culture significantly increased the level of alkaline phosphatase in comparison to those from the 2D culture [73].The heterogeneity of expression of several MSC surface markers is believed to arise from different subgroups within the MSC population, hence influencing significantly the MSC potency, including their osteodifferentiation potential [74]. In this regard, when correlating the osteogenic properties of GMSCs to the expression of MSC surface markers, in only one in vitro culture study, CD90 expression was evaluated during the osteodifferentiation of both BMSCs and GMSCs. Notably, the expression level of CD90 in BMSCs was gradually lost during their osteodifferentiation, while it stayed very high in GMSCs with a remarkable mineralized nodule formation [44]. CD90 antigen is one of the important markers of MSCs, and it can possibly serve as an index for CFU-F enrichment with strong osteogenic differentiation potential [75].CD90 (+) subpopulation from ADSCs was characterized with higher osteogenic potential identified via alkaline phosphatase (ALP) and Alizarin red staining [76]. Although previous studies recommended STRO-1 for the enrichment of MSC-like subpopulation from the gingiva and other connective tissues [29], a low percentage of MSCs and reduced level of STRO-1 during culture expansion were reported [77]. Moreover, although such findings highlighted the significant roles of stem cell markers on selecting GMSCs with higher osteodifferentiation potential, further investigations on the influences of site and donor variations, experimental designs, and isolation methods are necessary.To research thein vivo bone formation ability of GMSCs in different critical bone defects, in six in vivo studies, GMSCs were either injected systematically or mixed with different carriers before they were locally implanted. Although systematic delivery keeps cells in contact with oxygen and nutrient supply, some research studies approved that it may result in the concentration of MSCs in different sites of the body such as the lung, driven by inflamed organs. The benefit of local transplantation is the close proximity of MSCs to the site of the bone defect. However, the survival of MSCs may be affected due to insufficient oxygen and nutrients at the sites of injection. Therefore, further approaches should be applied to enhance cell engraftment and survival upon therapeutic transplantations [78].In animal studies included in the current review, almost all GMSCs formed new bone tissues with a lamellate pattern yet in different degrees. Wang et al. demonstrated that GMSCs loaded on collagen scaffolds have more expression of OPN and type 1 collagen when they were implanted in critical-sized mandibular and calvarial defects in rats than the free-cell scaffold group. Moreover, the newly formed bone was detected in both models eight weeks postoperatively [52].Similarly, GMSCs were implanted systematically via the tail vein into mandibular bone defects in mice; after three weeks of transplantation, new bone formation was significantly higher in the GMSC-loaded group than the unloaded one [68]. In a recent study, Al-Qadhi et al. also reported that GMSCs loaded on NanoBone were able to regenerate bone tissue in critical-sized bone defects in rabbits in a way comparable to BMSCs [48]. Admittedly, a desirable cell carrier should provide the biological template needed for cellular growth, differentiation, and tissue formation [79]. Despite the lower expression of bone-forming markers of GMSCs in comparison to that of BMSCs or PDLSCs, encapsulated GMSCs in RGD-modified alginate microspheres showed an ability to form new bone tissue after 8 weeks in a critical-sized calvarial defect in mice [66]. Ten weeks after implant recovery, GMSC- and BMSC-seeded biografts also showed a higher mineralized tissue with strong OCN expression than the unseeded one [58].In particular, GMSCs mixed with other cells in one culture or one construct lead to enhanced osteogenic differentiation [80, 81]. It is therefore important to realize that many factors might influence the regenerative capacity of MSCs, including different culture conditions and cell carriers. Indeed, various articles have demonstrated the positive or negative impact of different factors on the viability and osteogenic potential of GMSCs. These factors include the following: conditioned medium [82], growth factors [83, 84], drugs [85, 86], herbal medicine [87], and scaffold type [88] (Figure 5). However, studies using exogenous factors or coculture systems were excluded from this systematic review to precisely conclude the osteodifferentiation potential of GMSCs without any synergistic or confounding factors.Figure 5
Different factors influence the osteogenic potential of GMSCs.


## 5. Limitation in the Current Reviewed Studies

Even thoughin vitro culture preclinical research studies are considered a basic step for future research or for any novel therapeutic approach, it is worth mentioning that the methodological quality analysis of all evaluated in vitro culture studies shows some bias, such as lack of repetition of the experiments and lack of randomization, blinding, and sample size calculation. In spite of these factors that can influence the scientific validity of experimental results as all phases of the research process are interlinked, some researchers thought that those quality analyses could not be applied to in vitro culture studies [89]. For instance, the insufficient sample size might give incorrect results, which then may affect the outcomes of preclinical studies and in turn future clinical trials. We, therefore, found it is reasonable to apply the modified CONSORT guidelines [41] to in vitro culture studies to emphasize the importance of avoiding bias in future MSC research studies.Importantly, no clinical trials of bone tissue engineering by GMSCs were found. The authors believe that the reasons might ascribe either to an early judgment of the outcomes from preclinical studies or to insufficient data collected. To confirm whether the outcomes ofin vivo studies are not influenced by intended or unintended bias, all animal studies should have a clear study design. These parameters should include reporting of randomization, baseline characteristics (age, sex, and weight), animal housing conditions, blinding, animals enrolled and attrition, defect characteristics, follow-up, disclosing any adverse effects during and after the intervention, sample size, methods of size calculation, and reporting statistical analysis. This information will significantly improve the internal and external validity of any study and will also help researchers to publish a high level of scientific evidence similar to human RCTs.With respect to thein vivo studies, most studies revealed a probably low risk of bias in sequence, detection, reporting, and one metric of performance (identical across group study) domains, while another metric of performance (blinding) and attrition domains were not reported.


## 6. Conclusion

Although GMSCs show similar or lower osteodifferentiation potentialin vitro culture studies compared to other MSC sources, regenerating bony defects in vivo was significantly feasible with GMSCs. The easy accessibility and highly proliferative ability of GMSCs with a short doubling time could make them an attractive alternative source in the field of bone tissue engineering. However, the limited in vitro degree of osteodifferentiation potential of GMSCs remains a disadvantageous outcome. Therefore, further optimization of the in vitro culture conditions is needed.In the same way, due to the insufficient number ofin vivo studies that highlight the role of GMSCs in bone regeneration and based on the quality of the literature, using appropriate animal models with critical bone defects rather than ectopic models is highly important before going into a clinical application. Despite such findings for the benefit of using GMSCs in bone regeneration, well-designed preclinical studies that follow rigorous guidelines and manage a range of conditions such as experimental models, differentiating factors, culture media, and biological activity, cost-effectiveness, and safety of GMSCs are required.



---

*Source: 6698100-2021-06-14.xml*